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Abstract 
Introduction 
Invasive bacterial infections (IBI) cause significant morbidity and mortality in infants and young 
children, predominantly in low and middle-income countries. There are limited data on paediatric 
IBI, as well as the impact of pneumococcal conjugate vaccine (PCV) on the spectrum of IBI 
pathogens, in African countries with a high prevalence of HIV infection. We described the 
epidemiology of IBIs in a cohort of children <5 years of age in Soweto, South Africa.  
Objectives 
To estimate the incidence of IBI in children <5 years of age that participated in the 9-valent PCV 
(PCV9) efficacy trial, stratified by age, PCV9 vaccination status and HIV infection status, as well as to 
determine which pathogens are responsible for IBI among PCV9 vaccinated and unvaccinated, and 
HIV-infected and –uninfected hospitalised children.  
Methods 
A secondary data analysis was performed using a cohort of children enrolled into the PCV9 
randomised control trial (RCT) conducted in Soweto from 1998-2005. During this RCT, 39 836 
children were randomised to receive either PCV9 or placebo, and surveillance was conducted by 
study doctors in admission wards at Chris Hani Baragwanath Academic Hospital (CHBAH) to identify 
hospitalised participants. Incidence of IBI was calculated using person-time (with censoring occurring 
on each participant’s fifth birthday or date of death) and stratified by age group, sex, PCV9 
vaccination status and HIV infection status. Risk factors for IBI were investigated using binomial 
logistic regression.  
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Results 
A total of 395 cases of laboratory-confirmed IBI were included in the analysis. The incidence of all-
cause IBI hospitalisations decreased with increasing age. PCV9 vaccination was associated with 
reductions in incidence of all-cause IBI hospitalisation (IRR=0.76; 95% confidence interval (CI) 0.61 to 
0.93, p=0.006) which was predominantly due to the reductions in Streptococcus pneumoniae 
incidence (IRR=0.56; 95% CI 0.39 to 0.78, p<0.001). PCV9 vaccination was associated with a decrease 
in incidence of PCV9- and PCV9-related serotypes in HIV-infected (IRR=0.53; 95% CI, 0.20 to 0.85, 
p=0.005) and HIV-uninfected (IRR=0.44; 95% CI, 0.17 to 1.07, p=0.051) participants. PCV9 vaccination 
had no significant effect on the incidence of Haemophilus influenzae type b or Salmonella species 
infections, however, there was a trend towards higher incidence of infections due to Staphylococcus 
aureus, a trend towards decrease in incidence of Escherichia coli and a significant increase (IRR=3.50; 
95% CI, 1.10 to 14.59, p=0.019) in Klebsiella species IBI in PCV9 vaccinated children.  
Conclusion 
PCV9 vaccination was effective in reducing incidence of IBI hospitalisation in HIV-infected children 
through significant reductions in S. pneumoniae incidence. HIV-infected participants and those that 
did not receive PCV9 were at increased risk for IBI hospitalisation. Our results show that trends in 
other IBI causative pathogens (specifically Staphylococcus aureus and Klebsiella species) should be 
monitored in the post-PCV era. 
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1. Chapter One: Introduction  
This chapter will begin by giving a brief description and background on invasive bacterial infections 
(IBI) in children in terms of clinical manifestation and symptoms as well as introducing the common 
causative pathogens and risk factors for infection. The burden of disease and disease patterns 
globally will be described before looking specifically at burden of disease and disease patterns in 
Africa (in terms of how the epidemiology of IBI differs between low and middle-income settings 
compared to high income settings). The burden of disease and disease patterns in South Africa will 
then be described and the link between IBI and HIV infection explored. A summary on the 
background of PCV and its introduction into the South African immunisation program (EPI-SA) as 
well as current gaps in knowledge will then be given in order to provide context to this research 
project. The chapter will end with the main aims and objectives of this research project.  
1.1 Background and Literature Review  
 
1.1.1 Invasive Bacterial Infections  
Bacterial infections cause significant morbidity and mortality in infants and young children, 
predominantly in low and middle-income countries (LMIC) (1). These infections manifest clinically as 
pneumonia, meningitis, bacteraemia, urinary tract infections, infection of the musculoskeletal 
system, and acute otitis media amongst other infectious syndromes. IBI are characterised by the 
detection of bacteria in a normally sterile site such as blood (resulting in bacteraemia), or 
cerebrospinal fluid (CSF, resulting in meningitis) or other body fluids to a lesser extent (2). 
Pneumococcus (Streptococcus pneumoniae) and meningococcus (Neisseria meningitidis) are two of 
the most common bacterial causes of meningitis and bacteraemia globally (2).  
Many of the bacterial pathogens responsible for causing IBI are common colonisers of the 
nasopharynx in healthy individuals. Pneumococcus is an example of this, and is found to have very 
high nasopharyngeal colonisation rates in healthy children (3). Bacterial pathogens become invasive 
when they are able to cross the mucosal barrier and enter into the bloodstream. In some cases the 
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infection may cross the blood brain barrier, thereby entering the central nervous system, causing 
meningitis. There are several factors which increase the risk of bacterial colonisers becoming 
invasive. These risk factors also often increase the severity of the infection once the pathogen has 
become invasive, hence increasing the risk of complications and poorer outcomes. The most 
common risk factors for invasive pneumococcal infections in paediatric patients under the age of 5 
years, are immunosuppression or underlying conditions (including HIV and diabetes) (4), child-care 
attendance, overcrowded households and lack of breast-feeding (5). The increased risk associated 
with diabetes is especially relevant for high income countries where there is  a rise in non-
communicable, lifestyle-related illnesses which may increase the risk of IBI (4), however, LMICs are 
also starting to see higher rates of non-communicable diseases which is likely to intensify the 
problem in these areas (6). The most common risk factors for invasive meningococcal infections 
include exposure to cigarette smoke and living in close contact with another infected individual (4). 
Studies have shown that up to half of meningitis patients have an underlying condition which 
predisposes them to infection, with as many as one third of these patients being immune deficient 
(4). Repeated meningitis episodes have been linked to anatomical defects in which there is a 
disruption of the blood brain barrier (4).  
While an estimated 70% of bacteraemia episodes will resolve on their own and will not deteriorate 
clinically (7), the remaining infections will manifest clinically as pneumonia, septic arthritis, 
osteomyelitis, acute otitis media or sepsis (8). Sepsis in infants usually presents with fever, vomiting, 
skin rash, inability to feed and/or changes in breathing (7). Meningitis presents differently in 
different age groups (4). Generally, infants under the age of 3 months present with nonspecific signs 
such as lethargy, poor feeding and irritability; while older children tend to present with more typical 
symptoms such as neck stiffness and headache (4). Outcomes associated with meningitis are often 
severe, with up to 50% of meningitis survivors suffering permanent damage such as neurological 
deficits, cognitive impairment or hearing damage. Mortality rates attributed to meningitis are as 
high as 20% in high income countries, while rates are estimated to be higher in LMICs, reaching as 
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high as 45% in some settings (4, 9). The empiric treatment for all IBI cases is antibiotics, although 
regimens differ according to geographical location and clinical presentation (10). 
The pathogen profiles of IBI are relatively diverse among different age groups. Pneumococcal 
disease incidence is highest in young children (under 2 years of age) and the elderly (over 50 years of 
age). Meningococcal disease incidence is highest in children (over 1 month of age) and young adults 
(4). Vaccination against Haemophilus influenzae type b (Hib), S. pneumoniae and meningococcus 
using conjugate vaccines has caused a shift in the age distribution of bacterial meningitis from being 
a disease that mainly affected young children and adolescents, to one that predominantly affects the 
elderly (4). Studies in high income countries however, have demonstrated a decrease in incidence of 
IPD in the elderly as well as unvaccinated children due to the reduction in bacterial carriage in 
vaccinated children (known as herd immunity) (11, 12).  
1.1.2 Burden of disease and disease patterns globally 
Global statistics indicate that approximately 6.3 million children died before the age of 5 years in 
2013 (13). More than half of these deaths (51.8%) were due to infectious causes (including 
pneumonia, diarrhoea, sepsis and meningitis) (13). Of these deaths, 44% occur in the neonatal 
period (the first 28 days of life) and were exacerbated by preterm birth complications. In children 
aged 1-59 months the most common causes of death were injury (15%) and pneumonia (13%). The 
burden of paediatric deaths was disproportionately higher in LMICs compared to high income 
countries, with 49.6% of deaths occurring in sub-Saharan Africa and 32.1% occurring in southern 
Asia (13). It is estimated that nearly half of these deaths could have been prevented through 
vaccination, proper nutrition and increased access to health care (14). 
Globally the primary causative agents for bloodstream infections are considered to be 
Staphylococcus aureus, Escherichia coli and coagulase-negative staphylococcus (CoNS), although it is 
recognised that CoNS in most cases is a contaminant and is hence usually not clinically relevant (15). 
Other important causative agents include Enterococcus spp, Klebsiella spp, S. pneumoniae and 
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Enterobacter spp (15). In children less than 1 year of age the most frequently isolated pathogen is 
reported to be CoNS while S. pneumoniae is the most frequently isolated pathogen in children aged 
1-5 years. These estimates are taken from a surveillance study done between 1997 and 2002 in 
North America, Latin America and Europe (15). A population-based cohort study done in Switzerland 
between 2011 and 2015, highlighted E. coli (20%), S. aureus (15%), CoNS (11%) and S. pneumoniae 
(10%) as the leading pathogens causing bacterial sepsis in children under 17 years of age (16). Not 
only has the pathogen profile has been shown to vary somewhat between different age groups and 
geographical locations, but also between nosocomial versus community-acquired infections. 
Nosocomial bloodstream infections have been found to have much higher antibiotic resistance rates, 
especially those isolated from intensive care patients (15). In the United States it is estimated that 
36 000 deaths are caused by bloodstream infections annually. It is however acknowledged, that even 
in this high resource setting, there could be underreporting of the burden of disease. This 
underreporting is mainly due to the International Statistical Classification of Diseases and Related 
Health Problems (ICD) coding which often records the cause of disease as the underlying source of 
infection (which may differ to the diagnosis of IBI) and hence these events are not considered in 
some reports (17).  
The main causative agents for bacterial meningitis are S. pneumoniae  and N. meningitidis, with S. 
pneumoniae being responsible for as many as two thirds of cases in the United States and Western 
Europe post introduction of PCV (4). Other important causative agents include Group B 
streptococcus (GBS), E. coli, Haemophilus influenzae, Listeria monocytogenes, S. aureus and 
Salmonella spp (2).  
1.1.3 Burden of disease and disease patterns in Africa  
The leading causes of bloodstream infections in Africa according to a meta-analysis of studies 
between 1984 and 2006, are reported to be S. pneumoniae (18.3%), Salmonella enterica (13.5%), S. 
aureus (9.5%) and E. coli  (7.3%) with the majority of infections being due to Gram-negative bacteria 
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(18). Invasive bacterial infections in Africa and other low income settings differ in three main ways 
compared to high income settings. A summary of these three main differences is given below. The 
first is that the burden of IBI is several fold higher in LMICs than in higher income settings. Secondly, 
the epidemiology and aetiology of infections are different, and thirdly, the severity of outcomes due 
to IBI is increased in LMICs compared to higher income settings.  
1.1.3.1 Burden of IBI in Africa 
Overall sepsis and meningitis rates are much higher in sub-Saharan Africa and south Asia compared 
to the rest of the world (13).  Bacterial meningitis is approximately 10 times more common in LMICs 
than high income areas across all age groups (4). These estimates are taken from reported infection 
rates however, it is widely acknowledged that this is likely to be a considerable underestimation due 
to lack of surveillance and monitoring, coupled with inadequate diagnostic and laboratory resources 
in these areas (19). Some of the most important risk factors for IBI in children under-5 years of age 
include: being born in a rural area, being born to poor households and being born to a mother who 
lacks basic education (14). These risk factors also partly explain why mortality and morbidity due to 
IBI are so high in African children.  
1.1.3.2 Aetiology and epidemiology of IBI in Africa 
Approximately 99% of infant deaths occur in LMICs. Most available data however, is generated 
through investigation of the 1% of deaths that occur in high income countries (20). While these data 
are often extrapolated to other settings, the validity of doing so is questionable due to population 
differences as well as differences in epidemiology of infections across different geographical 
locations (5). Since IBI antibiotic treatment is usually started empirically before culture confirmation 
of the presumed organism, it is necessary to rely on accurate knowledge of the bacterial pathogen 
prevalence as well as resistance patterns in the specific geographical location in order to inform the 
choice of antibiotic treatment (21). The variation in IBI patterns is further magnified by the high 
prevalence of HIV in Africa, and coinfection with malaria in the more tropical latitudes (18). 
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Approximately 90% of HIV-infected individuals worldwide live in LMICs, with 75% living in sub-
Saharan Africa (4, 20). Data indicate that HIV-infected adults are more likely to acquire hospital-
associated infections (specifically Salmonella spp and S. aureus) than HIV-uninfected individuals (21). 
Nosocomial infections and their ensuing morbidity and mortality in turn, often have a negative 
impact on health seeking behaviour due to poor reputation of health services in the community (19). 
The high rates of nosocomial infections in Africa point to issues with training and knowledge on basic 
infection control as well as inadequate health infrastructure, technology and thus, ultimately, to 
resource deficiencies (22). Another layer of complexity is that HIV-infected infants are usually 
exposed to co-trimoxazole prophylaxis (South African guidelines indicate that all HIV-infected and –
exposed infants must receive co-trimoxazole prophylaxis from 4-6 weeks of age (23)) which could 
increase the risk of antibiotic resistance in this already vulnerable group (21). During the study time 
period, HIV treatment guidelines recommended co-trimoxazole prophylaxis for any child that tested 
positive for HIV on Elisa or PCR (and should be continued until CD4 count >200 cells/mm3) (24). 
Antibiotic resistance would not only change patterns of disease at a population level but would also 
increase severity of disease at an individual level, especially in cases in which there are few 
alternative treatments available. The types of infections identified in African studies (specifically 
Gram-negative bacilli and S. aureus) also indicate a lack of adequate hygiene levels (especially at 
hospitals) and poor postnatal care (19). 
1.1.3.3 Severity of IBI in Africa 
The case fatality rate of bloodstream infections in Africa for all ages is estimated to be 18.1% 
compared to 13.0% in the United States (17, 18). There are several reasons for this, including poor 
healthcare, shortage of antibiotics, delays in treatment and lack of microbiological diagnostic 
services. A meta-analysis done on African bloodstream infections for all ages highlighted a number 
of cases presenting with fever, which were mistaken to be malaria cases. The misdiagnosis resulted 
in antibiotics being withheld which in turn resulted in increased mortality (18). The analysis also 
found that 5.8% of children admitted with malaria had bacterial bloodstream coinfections which 
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were untreated (18). Many of these settings did not have diagnostic capacities for non-malarial 
bloodstream infections.  Another reason for poorer outcomes in African patients is the increase in 
prevalence of underlying conditions, especially HIV. Studies have shown increased case fatality rates 
of IBI in HIV-infected individuals (25).  This demonstrates that not only are the patterns of disease 
different for HIV-infected individuals, but the outcomes of disease are more severe (4). This places a 
burden on systems already burdened by substantial costs involved in treating HIV-infected patients. 
Despite the differences between IBI in HIV-infected and HIV-uninfected individuals, the guidelines 
for treatment remain the same (21). 
1.1.4 Burden of disease and disease patterns in South Africa 
Although there are limited data on IBI in South Africa, a study done on paediatric bloodstream 
infections (including children aged 0-14 years), between 2008 and 2013 at a Western Cape Hospital, 
showed that that these infections were dominated by Klebsiella pneumoniae (17%), S. aureus (14%), 
E. coli (11%) and S. pneumoniae (11%) (26). Streptococcus pneumoniae declined from 12.5% in 2008-
2010 to 8.3% in 2011-2013 (p=0.04), likely due to the introduction of PCV in 2009. The study found 
that nosocomial infection and HIV infection were significant predictors of mortality (27). As much as 
47% of the analysed events were nosocomial with high rates (70%) of antibiotic resistance. 
Streptococcus pneumoniae was demonstrated to be significantly more common in HIV-infected than 
HIV-uninfected individuals (17.2% versus 6.7%, p<0.001) (27).   
The burden of IBI in South Africa is closely linked to the prevalence and treatment of HIV. In 2005 it 
was estimated that approximately 30% of pregnant women attending public health clinics in South 
Africa were HIV-infected (28). The South African prevention of mother-to-child transmission 
programme (PMTCT) has been extremely successful, despite its late start in 2003. This has resulted 
in a reduction of vertical transmission rates from mother to infant from a projected 30% (in the 
absence of PMTCT) to 2.7% in 2011 (28). Before the rollout of antiretroviral therapy (ART) by the 
National Department of Health, South Africa in 2004, HIV infections were estimated to account for 
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just under a third of paediatric admissions at CHBAH (29, 30). HIV-infected children were treated 
with antibiotic prophylaxis only to prevent opportunistic infections after their first admission, as 
testing was done only in patients clinically suspected of having HIV infection (30). HIV prevalence 
decreased from 31.7% of paediatric admissions at CHBAH in 2005 to 19.3% in 2010-11 following the 
successful rollout of the ART program (29). The relationship between HIV with ART and IBI is 
demonstrated by the 50.8% (95% confidence interval (CI), 41.5% to 58.7%) reduction in invasive 
pneumococcal disease (IPD) in HIV-infected children between the pre- and post-ART introduction 
periods (31). This study was done before the introduction of PCV into the EPI-SA and there was no 
reduction of IPD seen among the HIV-uninfected children; hence the reduction in HIV-infected 
children was attributed to the introduction of ART (31). 
1.1.5 Pneumococcal Conjugate Vaccine  
In 1929, Avery and Goebel first described enhancing the immunogenicity of bacterial polysaccharide 
antigens by attaching them to a protein carrier molecule (32). The immaturity of the immune system 
in infants and young children makes it difficult for them to mount a protective antibody response 
against polysaccharide antigens. By introducing a protein carrier into these vaccines, a protective 
immune response can be mounted in this high risk group, providing  them with some degree of 
immunity (32). In 1987, the Hib vaccine became the first glycoconjugate vaccine to be licensed for 
use in humans (32). In 1998 the first PCV efficacy study (using PCV7 – a vaccine containing cell 
capsule polysaccharides of 7 of the over 90 pneumococcal serotypes), conducted in the United 
States, was published and indicated a 100% efficacy against IPD (32). The success of these two 
vaccines in reducing disease has been attributed partially to the reduction in invasive disease and 
partially to the reduction of nasopharyngeal carriage of pathogens in vaccinated individuals and 
resulting in a reduction of person-to-person spread (32).  
An important RCT was conducted in Soweto from 1998-2005 to determine the efficacy of the 9-
valent PCV (PCV9) (33). The PCV9 included pneumococcal serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F and 
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23F (33). Results of this study, which randomised 39 836 children to receive either PCV9 or placebo, 
were crucial in the decision to introduce PCV into the EPI-SA in 2009. The study demonstrated an 
83% reduction in IPD (caused by vaccine serotypes) in HIV-uninfected children and a 65% reduction 
in IPD (caused by vaccine serotypes) in HIV-infected children. There was a 63% decrease in IPD 
caused by vaccine-related serotypes (6A, 19A and 19B) in HIV-infected children. There was a 
significant decrease in incidence of radiologically-confirmed pneumonia as well as antibiotic 
resistant IPD in PCV9 recipients (33). PCV was introduced into the EPI-SA as a 7-valent formulation 
(PCV7) in 2009 (34). The vaccine schedule consisted of 2 primary doses at 6 and 14 weeks, with a 
booster dose at 9 months of age (2 + 1 regimen). PCV7 was replaced with a 13-valent formulation 
(PCV13) in 2011, using the same vaccination schedule (35).  
A national study of South African children under 2 years of age demonstrated that 4 years after the 
introduction of PCV into EPI-SA, there was an 89% reduction in incidence of IPD caused by PCV7 
serotypes and an 82% reduction in the incidence of penicillin non-susceptible serotypes (34). There 
was also a notable (50%) reduction of IPD caused by PCV7 serotypes in unvaccinated adults and a 
30% reduction in children too young to have been vaccinated (34). Reductions in IPD observed in the 
age groups not eligible to have received PCV most likely reflect the ‘indirect protection’ or ‘herd 
immunity’ offered by vaccine associated  reduction of pneumococcal carriage in the population (34). 
This is important in protecting vulnerable age groups such as neonates (who are too young to 
receive PCV themselves).  The effectiveness of PCV13 has also been demonstrated through a case-
control study in South African children which showed an 85% (95% CI, 37 to 96) effectiveness among 
HIV-uninfected children and a 91% (95% CI, 35 to 100) effectiveness among HIV-infected children in 
preventing IPD due to PCV13 serotypes (35).  
Despite the reduction of burden of disease induced by the vaccination, there has been an increase in 
disease caused by non-vaccine serotypes and other microbes, called replacement (36).  Patterns of 
replacement are difficult to predict due to the fact that there are over 90 pneumococcal serotypes, 
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only 13 of which are included in the vaccine (36). Replacement disease has also been reported for 
other vaccines after they had been introduced into communities. For example, in a population with 
high vaccine coverage of Hib, there has been reported replacement disease in which non-type b H. 
influenzae (specifically type a and non-typeable strains) have increased significantly (from 0.6 per 
100 000 to 5.6 per 100 000) (37).  
1.1.6 Current gaps in knowledge 
The epidemiology of IBI in Africa is not well documented. Since the increased access to HIV 
prevention programmes, improved HIV treatment and the high coverage of PCV, the epidemiology 
of IBI is expected to show significant changes (26). An important aspect of current IBI studies is the 
change in infection patterns due to vaccination (through the replacement phenomenon as seen with 
PCV and Hib) as well as the rise of antibiotic resistant bacterial strains through the overuse of 
antibiotics. A study in Ethiopia reported that most bacterial strains isolated from blood were 
resistant to more than three commonly used antibiotics, with all Gram-negative bacterial isolates 
being resistant to ampicillin (10). This not only highlights the importance of vaccine development 
against bacterial pathogens, but also of the timely investigation of bacteraemia events and 
monitoring of antibiotic resistance patterns (10).  In order to quantify the burden of IBI and to better 
understand the risk factors, further research on IBI aetiology and epidemiology in African children is 
required (26).  
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1.2 Problem Statement 
The epidemiology of IBI is poorly documented in LMICs (26). In African countries with a high 
prevalence of HIV infection little is known about IBI, especially subsequent to the introduction of 
PCV (27). Although there are several South African studies on the effect of PCV on IPD rates (34, 38), 
less is known about the potential impact of PCV on the spectrum of IBI pathogens in both HIV-
infected and HIV-uninfected children. Replacement disease may result in increased non-vaccine 
serotypes as well as the possibility of a change in incidence of other bacterial pathogens.  The aim of 
this research was to determine whether HIV infection and PCV9 vaccination status had an effect on 
the epidemiology and aetiology of laboratory-confirmed IBI in children <5 years of age that 
participated in the PCV9 efficacy trial (1998-2005) in Soweto South Africa.  
 
1.3 Objectives 
1. To estimate the incidence of IBI in children <5 years of age that participated in the PCV9 
efficacy trial in Soweto, stratified by age group (<6 months, 6-11 months, 12-17 months, 18-
23 months, 24-35 months and 36-59 months), PCV9 vaccination status and HIV infection 
status.  
2. To determine the risk factors associated with severe IBI (defined as death or prolonged 
hospitalisation) in the cohort.  
3. To describe the seasonality of IBI in this cohort over the study time period (1998-2005).  
4. To determine the pathogens responsible for IBI among PCV9 vaccinated and unvaccinated as 
well as HIV-infected and –uninfected hospitalised children <5 years of age.  
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2. Chapter Two: Materials and Methods  
This chapter gives an overview of the analysis, beginning with a description of the original study on 
which this analysis is based. The important definitions used for the analysis are then outlined and 
statistical analytical methods are described in detail. The chapter ends with details of the ethical 
approval for the research project.  
2.1 Original Study Design and Population 
A RCT assessing efficacy of the PCV9 was conducted in Soweto from 1998-2005 (33). A total of 
39 836 children from Soweto were randomly assigned to receive vaccination with either PCV9 or 
placebo at 6, 10 and 14 weeks of age. Children were eligible for inclusion in the study if they were 
between 28-84 days old and were unvaccinated or had received only routine Bacillus Calmette-
Guérin vaccine and oral poliovirus vaccine at birth (33). Children were excluded if they had a 
progressive underlying neurological disorder, a history of seizures or infantile spasms or if there was 
a high likelihood of them moving from Soweto (33). Enrolment took place between 2 March 1998 
and 30 October 2000 (33). The paediatric admission wards at CHBAH were monitored 24 hours a day 
and all study participants admitted for any cause were examined by a study doctor. Case report 
forms were completed for all admitted participants. Surveillance of paediatric admission wards 
continued until October 2005 (33). The study doctors were not involved in the decision to hospitalise 
a child, or any management decisions while hospitalised. CHBAH is a secondary and tertiary hospital 
that is estimated to attend to more than 90% of children in Soweto (33). Although Hib conjugate 
vaccine was only included into the EPI-SA in 1999, all PCV9 efficacy study participants received Hib 
vaccine as part of routine study procedure. EPI-SA vaccines received by study participants included 
diphtheria, tetanus, whole-cell pertussis, hepatitis B, and oral live trivalent poliovirus vaccine (33).  
HIV testing was not done universally during this time period and hence only participants in whom 
HIV was clinically suspected were tested. HIV infection was confirmed by HIV DNA polymerase-
chain-reaction (PCR) for children under the age of 18 months and by enzyme-linked immunosorbent 
13 
 
assay (ELISA) for children 18 months or older. For those children in whom HIV was clinically 
suspected but ELISA results were negative, a PCR was used to evaluate status (33). It was assumed 
that participants who were not hospitalised during the follow up period were HIV-uninfected since 
no HIV treatment would have been given and hence it is unlikely that an HIV-infected, untreated 
child would not have presented to the hospital with an opportunistic infection at some stage during 
this time period. Hospitalised participants without HIV results were also assumed to be HIV-
uninfected since HIV was not clinically indicated and hence testing was not done in these cases 
(although the majority of hospitalised children were tested for HIV).    
Bacteria were isolated from blood samples using an automated blood-culture system (BacT-Alert, 
OrganonTeknika) and from cerebrospinal fluid (CSF) using standard microbiologic procedures. 
Routine microbiologic methods were used to identify species (33).  
2.2 Definitions 
The current study comprises a secondary data analysis in the form of a retrospective cohort study. 
The incidence of hospitalisation for IBI was determined in the cohort of children under 5 years of 
age. Cases were laboratory-confirmed IBI. The definition used for IBI in the main analysis was the 
isolation of a bacterial organism from a non-contaminated blood culture. A new episode of infection 
was defined as isolation of a bacterial pathogen at least 30 days after the previous episode, or the 
isolation of a different pathogen within 30 days after the previous episode. An infection was 
considered to be a single episode if the same pathogen was found in the same or another site taken 
within 30 days of the original infection or during the same hospital admission period. Only admission 
cultures were analysed and hence infections were assumed to be community-acquired. Infections of 
the CSF were not included in the primary analysis but were presented separately. Blood cultures 
were done for most hospitalised cases whereas very few children had CSF cultures taken. The 
decision was hence taken to restrict the primary analysis to blood cultures in order to increase the 
specificity of the analysis as well as to increase the clinical relevance for treatment. Hospitalised 
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participants without blood cultures were assumed to be negative for IBI since the attending 
physician would have seen no clinical indication of bacteraemia and hence would not have 
requested a blood culture for these cases.  
2.3 Statistical Analysis 
Person-time calculations were done with censoring time occurring at each participant’s fifth birthday 
or date of death (for participants that were reported to have died during hospital admission). 
Multiple events were counted per participant (given that the events were separated by at least 30 
days or different pathogens were isolated within 30 days). Bacterial cultures were categorised as S. 
pneumoniae, Hib, E. coli, S. aureus, Klebsiella spp, Salmonella spp or other. The ‘other’ category 
included Pseudomonas aeruginosa, Campylobacter spp, Moraxella catarrhalis, Streptococcus spp 
(excluding S. pneumoniae), Enterococcus faecalis, Alcaligenes spp, Morganella morganii, 
Acinetobacter lwoffii, Candida albicans, Shigella flexneri, N. meningitidis, Haemophilus 
parainfluenzae, Citrobacter freundii, Mycobacterium tuberculosis, Escherichia vulneris, and non-
typable Haemophilus influenzae. The following organisms were considered contaminants: 
Corynebacterium spp, Bacillus spp, Propionibacterium spp, Viridans streptococci, Lactobacillus spp, 
coagulase-negative staphylococcus (including Staphylococcus epidermidis), Peptostreptococcus spp, 
Clostridium bifermentans, Micrococcus spp, Streptococcus spp, other Gram-positive cocci and 
Neisseria subflava, and were excluded from the primary analysis. Contaminants were reported 
separately as some of these events may be considered clinically significant in certain circumstances 
(including HIV-infected or premature children). The numerator for incidence calculations was the 
number of IBI events while the denominator was person-time in years. All incidence rates are 
reported per 10 000 person years.  
Participants were classified into four study groups (HIV-uninfected placebo recipients (HIV-PCV-), 
HIV-uninfected PCV9 recipients (HIV-PCV+), HIV-infected placebo recipients (HIV+PCV-) and HIV-
infected PCV9 recipients (HIV+PCV+)). Incidence was stratified by age group (<6 months, 6-11 
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months, 12-17 months, 18-23 months, 24-35 months and 36-59 months), sex, PCV9 vaccination 
status, HIV infection status and the four study groups (HIV-PCV-; HIV-PCV+; HIV+PCV-; HIV+PCV+). 
Ninety-five percent confidence intervals for incidence rates were calculated using the Poisson 
distribution. Incidence rate ratios (IRR) were calculated to compare the incidence rates in different 
groups and p-values presented to indicate significance. The power to determine the difference in 
proportions between the study groups was calculated given the sample size and an alpha of 0.05. 
Seasonality was investigated by comparing incidence of IBI events occurring in summer (September 
through February) versus winter (March through August).  
Risk factors for IBI hospitalisation were investigated using binomial logistic regression modelling for 
the outcome of IBI. The following risk factors were included: PCV9 vaccination status, sex, HIV 
infection status and prematurity (preterm defined as born <37 weeks of gestation, and term defined 
as born ≥37 weeks of gestation). Gestational age was included on the initial enrolment questionnaire 
for all participants; however birthweight was only collected for some hospitalised participants. Only 
1515 participants (3.8%) had a recorded birthweight, whereas gestational age was recorded for 
almost all participants (99. 9%). Hence gestational age was used as a measure of prematurity in the 
logistic regression models as a risk factor for IBI. This is a limitation of the dataset as it was not 
possible to investigate birth weight as a risk factor for IBI. All independent variables were included in 
the model (rather than using stepwise modelling) since all were considered clinically important with 
regards to the outcome, based on existing literature (34, 39). Age was not included as an 
independent variable in the model since participants that were not hospitalised during the follow up 
time did not have a recorded age (only hospitalised participants had an age at which they were 
hospitalised). This had no effect on the model since age was already controlled for (between study 
groups) due to all participants being enrolled at the same age and followed up until 5 years of age. 
Odds ratios (OR) with 95% CI for the univariate and multivariate analysis were determined. 
Coagulase-negative staphylococcus was regarded as a contaminant for the purpose of this analysis, 
however literature indicates that this group (specifically S. epidermidis) may be pathogenic in certain 
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cases (40). Risk factors for CoNS infection were also investigated using binomial logistic regression 
modelling (as described above for IBI hospitalisations). A second analysis of CoNS infections was 
done with events limited only to those in participants under 3 months of age (as CoNS infections 
were likely to be clinically significant in these young children).   
The following clinical characteristics of IBI were investigated individually using Chi-squared tests to 
determine if there was an association with specific IBI pathogens (S. pneumoniae, Hib, E. coli, S. 
aureus, Klebsiella spp, Salmonella spp or other - as defined above): fever, refusal to eat, vomiting, 
diarrhoea, weight-loss, night sweats, seizures and excessive crying. Univariate analysis using 
multinomial logistic regression was done to compare the clinical characteristics of Hib, E. coli, S. 
aureus, Klebsiella spp, Salmonella spp and other bacterial infections to those of S. pneumoniae 
infections. This investigation was cross-sectional (at time of hospitalisation) and included only 
participants hospitalised with IBI. 
Severity of IBI was modelled using a logistic regression model with a binary outcome of ‘survived’ or 
‘died’ as well as duration of hospitalisation (with a binary outcome of ‘≤4 days’ or ‘>4 days’). Four 
days was chosen as the cut-off for this severity model since CHBAH uses a four day rotation which 
generally discharges children on or before the fourth day if possible. Children that are severely ill are 
generally hospitalised for longer than four days. These models included only participants 
hospitalised with IBI in order to compare outcomes between infections with different pathogens. 
The independent variables bacterial type (S. pneumoniae, Hib, E. coli, S. aureus, Klebsiella spp, 
Salmonella spp or other - as defined above), HIV infection status, age category (<6 months, 6-11 
months, 12-17 months, 18-23 months, 24-35 months and 36-59 months), sex, PCV9 vaccination 
status and prematurity (as a categorical variable) were included in the models. Age was included in 
severity models since only participants that were hospitalised for IBI were analysed (as cross-
sectional data) and hence all had age at hospitalisation.  
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Stata software, version 13 (StataCorp, College Station, TX) was used for all analyses and a 
significance level of p<0.05 was used for all calculations. 
2.4 Ethical Approval  
This study was approved by the University of the Witwatersrand Human Research Ethics Committee 
(Medical): Clearance Certificate No. M161182 (Appendix 1) on the 25th November 2016. 
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3. Chapter Three: Results  
This chapter describes the results from the analysis starting with an overall description of IBI events 
in the cohort, in terms of incidence rates of the main causative pathogens and patterns of infection. 
The effect of PCV9 vaccination on IBI incidence rates and causative pathogens is then described, 
focusing on the differences between HIV-infected and –uninfected participants. The risk factors for 
IBI infection (including a separate description of risk factors for CoNS infection) are then described, 
and an overview of the main clinical characteristics and outcomes of IBI given. The chapter ends with 
a description of the invasive Klebsiella spp events in the cohort.  
3.1 Description of IBI events in the cohort  
From the 39 836 participants included in the RCT (19 922 of which received PCV9 vaccination and 
19 914 of which received placebo), there were 10 516 hospitalisation events. HIV status was only 
confirmed for 5 307 participants (1 267 of whom were HIV-infected and 4 040 of whom were HIV-
uninfected). It was assumed, as described in the methods, that those that were not tested for HIV 
were HIV-uninfected.  
A description of the 10 516 hospitalisation events is given in Figure 3.1. The PCV9 vaccinated arm 
contributed to 5 180 (49.3%) of the hospital events, while the placebo vaccinated arm contributed to 
5 336 (50.7%) of the hospital events. The PCV9 vaccinated arm was made up of 1 394 (26.9%)  HIV-
infected participants of whom 1 131 (81.1%) had blood cultures taken. Only 100 (8.8%) of these 
blood cultures were IBI positive. The HIV-uninfected participants made up 3 786 (73.1%) of the PCV9 
vaccinated arm. A total of 2 547 (62.3%) had blood cultures taken, of which only 70 (2.8%) were IBI 
positive. The placebo vaccinated arm was made up of 1 561 (29.3%) HIV-infected participants of 
whom 1 260 (80.7%) had blood cultures taken. Only 150 (11.9%) of these blood cultures were IBI 
positive. The HIV-uninfected participants made up 3 775 (70.8%) of the placebo vaccinated arm. A 
total of 2 599 (68.9%) had blood cultures taken, of which only 75 (2.9%) were IBI positive. 
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Total 
hospitalisations 
N = 10 516 
PCV9 vaccinated  
N = 5 180  
HIV-infected  
N = 1 394 
Blood culture taken 
N = 1 131 
IBI positive 
N = 100 
HIV-uninfected 
N = 3 786 
Blood culture taken 
N = 2 547 
IBI positive 
N = 70 
Placebo vaccinated  
N = 5 336 
HIV-infected 
N = 1 561 
Blood culture taken 
N = 1 260 
IBI positive  
N = 150  
HIV-uninfected 
N = 3 775 
Blood culture taken 
N = 2 599 
IBI positive  
N = 75  
 
 
 
 
 
 
Figure 3.1: Flow diagram indicating number of hospitalisation events in the cohort  
 
There were a total of 395 laboratory-confirmed IBI events in the total cohort over the follow up 
period (excluding contaminants which are described in the Appendix – Table S1). Males had 220 IBI 
events (99 in the PCV9 vaccinated group and 121 in the placebo group, p=0.036) while females had 
175 events (71 in the PCV9 vaccinated group and 104 in the placebo group, P<0.001). The median 
age for hospitalisation with IBI was 9.3 months (interquartile range (IQR), 4.1-21.0), with 8.7 months 
(IQR, 4.5-20.3) for PCV9 vaccinated and 9.3 months (IQR, 3.5-23.3) for placebo group (p=0.497). Of 
the 395 events, 250 (63.3%) occurred in HIV-infected participants (100 in the PCV9 vaccinated group 
and 150 in the placebo group) and 145 (36.7%) were in HIV-uninfected participants (70 in the PCV9 
vaccinated group and 75 in the unvaccinated group). The number of IBI events in the HIV-infected 
participants was very high considering that HIV-infected participants constituted only 3.2% of the 
total cohort (1 267 participants). Overall, there were 35 participants that had repeat IBI 
hospitalisations which were considered as separate events for the purposes of the analysis (15 were 
in the PCV9 vaccinated group and 20 in the placebo group) (Table 3.1).  
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Table 3.1: Characteristics of the participants with IBI events included in the analysis 
Characteristic  PCV9 (N=170) Placebo (N=225)  Total (N=395)  
Sex 
Male (%) 
 
99 (58.2%) 
 
121 (53.8%) 
 
220 (55.7%) 
Female (%) 71 (41.8%) 104 (46.2%) 175 (44.3%) 
Age at hospitalisation – 
median (IQR) in months 
8.7 (4.5-20.3)  9.3 (3.5-23.3)  9.3 (4.1-21.0) 
HIV Status  
Infected 
 
100 (58.8%) 
 
150 (66.7%) 
 
250 (63.3%) 
Uninfected 70 (41.2%) 75 (33.3%) 145 (36.7%) 
Number of with repeat 
hospitalisations 
15 (8.8%) 20 (8.9%) 35 (8.9%) 
 
Figure 3.2 shows the proportions of contributing pathogens responsible for the 395 IBI events. The 
commonest bacterial isolate was S. pneumoniae which was detected in 154 events (39.0%). E. coli 
was detected in 84 events (21.3%), S. aureus in 29 events (7.3%), Salmonella spp in 26 events (6.6%), 
Hib detected in 23 events (5.8%), Klebsiella spp were detected in 18 events (4.6%) and the remaining 
61 events (15.4%) were due to other pathogens (including Streptococcus spp (2. 8%), P. aeruginosa 
(2.3%), N. meningitidis (2.0%), A. lwoffii (1.5%), Campylobacter spp (1.5%), E. faecalis (1.5%), C. 
albicans (0.8%), Alcaligenes spp (0.5%), M. morganii (0.5%), M. tuberculosis (0.5%), C. freundii 
(0.3%), E. vulneris (0.3%), non-typable H. influenzae (0.3%), H. parainfluenzae (0.3%), M. catarrhalis 
(0.3%), and S. flexneri (0.3%)) which were grouped for the purpose of this analysis. A summary of the 
pathogens grouped as ‘other’ is presented in the Appendix (Figure S1).    
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Figure 3.2: The proportions of pathogens detected in IBI events in the cohort during hospitalisation 
 
Table 3.2 presents the incidence rates (per 10 000 person-years (PY) of follow up time) for bacterial 
pathogens detected as non-contaminated blood cultures during hospitalisation (number of events 
are presented in Table S2 – Appendix). Streptococcus pneumoniae had the highest incidence rate 
(8.01; 95% CI, 6.80 to 9.38), followed by E. coli (4.37; 95% CI, 3.49 to 5.41). The incidence of S. 
pneumoniae was significantly higher than E. coli (IRR 1.83, p<0.001). Klebsiella spp had the lowest 
incidence (0.94; 95% CI, 0.56 to 1.48). The incidence of S. pneumoniae was 8.56 (p<0.001) times 
higher than the incidence of Klebsiella spp.  
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Table 3.2: Incidence of IBI hospitalisation (per 10 000 person-years - showing 95% confidence intervals) 
Characteristic S. 
pneumoniae   
PCV9 
serotypes*  
Non-PCV9 
serotypes*  
Hib  E. coli   S. aureus  Klebsiella 
spp 
Salmonella 
spp 
Other** All  
Overall 8.01 (6.80-
9.38)  
5.67 (4.66-
6.84) 
1.35 (0.88-
1.98)  
1.20 (0.76-
1.80) 
4.37 (3.49-
5.41) 
1.51 (1.01-
2.17) 
0.94 (0.56-
1.48) 
1.35 (0.88-
1.98)  
3.17 (2.43-
4.08) 
20.55 (18.57-
22.68) 
Age Group  
 
<6 months***  
 
28.99 (20.98-
39.05)  
 
15.51 (9.83-
23.27)  
 
6.74 (3.23-
12.40)  
 
4.05 (1.48-
8.81) 
 
22.25 (15.32-
32.25) 
 
10.11 (5.66-
16.68) 
 
6.07 (2.77-
11.52) 
 
5.39 (2.33-
10.63) 
 
18.88 (12.55-
27.29) 
 
95.75 (80.65-
112.85) 
6-11 months 15.18 (10.24-
21.67) 
9.61 (5.79-
15.01)  
3.04 (1.11-
6.61)  
4.05 (1.75-
7.98) 
12.65 (8.19-
18.67) 
2.02 (0.55-
5.18) 
1.52 (0.31-
4.44) 
2.53 (0.82-
5.90) 
5.56 (2.78-
9.96)  
43.51 (34.80-
53074)  
12-17 months 11.15 (6.99-
16.88) 
9.12 (5.40-
14.41)  
1.01 (0.12-
3.66)  
1.52 (0.31-
4.44) 
4.56 (2.09-
8.66) 
1.52 (0.31-
4.44) 
1.01 (0.12-
3.66) 
3.04 (1.12-
6.62) 
3.55 (1.43-
7.31) 
26.35 (19.68-
34.55) 
18-23 months 6.59 (3.51-
11.27) 
5.58 (2.78-
9.98)  
5.58 (2.78-
9.98) 
0.51 (0.1-
2.83) 
2.53 (0.82-
5.92) 
1.01 (0.12-
3.66) 
0.51 (0.01-
2.82) 
0.51 (0.01-
2.82) 
2.53 (0.82-
5.92) 
14.20 (9.43-
20.52) 
24-35 months 4.31 (2.51-
6.90) 
3.30 (1.76-
5.64)  
0.76 (0.16-
2.22) 
0.51 (0.6-
1.83) 
2.54 (1.22-
4.66) 
0.52 (0.01-
1.41) 
0.76 (0.16-
2.22) 
1.52 (0.56-
3.31) 
1.52 (0.56-
3.31) 
11.41 (8.33-
15.27) 
36-59 months  3.68 (2.46-
5.29) 
3.17 (2.05-
4.68) 
0.51 (0.14-
1.30) 
0.38 (0.08-
1.11) 
0.25 (0.03-
0.92) 
0.51 (0.14-
1.30) 
0 (0- 
0.47) 
0 (0- 
0.47) 
0.51 (0.14-
1.30) 
5.33 (3.84- 
7.20) 
Sex  
 
Male  
 
8.61 (6.86-
10.67) 
 
6.43 (4.93-
8.24) 
 
1.14 (0.57-
2.04) 
 
1.14 (0.57-
2.04) 
 
5.19 (3.85-
6.84) 
 
1.87 (1.11-
2.95) 
 
1.04 (0.50- 
1.91) 
 
1.14 (0.57-
2.04) 
 
3.84 (2.70-
5.29) 
 
22.82 (19.90-
26.04) 
Female 7.41 (5.79-
9.35) 
4.91 (3.61-
6.53) 
1.57 (0.88-
2.58) 
1.25 (0.65-
2.19) 
3.55 (2.46-
4.96) 
1.15 (0.57-
2.05) 
0.84 (0.36-
1.65) 
1.57 (0.88-
2.58) 
2.51 (1.61-
3.73) 
18.27 (15.66-
21.19) 
IRR (p-value)  1.16 (0.356) 1.31 (0.163) 0.73 (0.432) 0.91 (0.827) 1.46 (0.088) 1.63 (0.207) 1.24 (0.658) 0.73 (0.432) 1.53 (0.103) 1.25 (0.028) 
Vaccination  
 
PCV9  
 
5.72 (4.31-
7.45) 
 
3.64 (2.54-
5.06) 
 
1.56 (0.87-
2.57) 
 
1.14 (0.57-
2.05) 
 
1.14 (0.57-
2.05) 
 
1.98 (1.19-
3.09) 
 
1.46 (0.80-
2.44) 
 
1.25 (0.64-
2.18) 
 
2.70 (1.77-
3.96) 
 
17.68 (15.12-
20.55) 
Placebo 10.31 (8.38-
12.55) 
7.70 (6.05-
9.67) 
1.15 (0.57-
2.05) 
1.25 (0.65-
2.18) 
5.31 (3.95-
6.98) 
1.04 (0.50-
1.91) 
0.42 (0.11-
1.07)  
1.46 (0.80-
2.45) 
3.64 (2.54-
5.07) 
23.42 (20.46-
26.69) 
IRR (p-value) 0.56 (<0.001) 0.47 (<0.001) 1.36 (0.443)  0.92 (0.838) 0.65 (0.050) 1.90 (0.099) 3.50 (0.019) 0.86 (0.700) 0.74 (0.252) 0.76 (0.006) 
HIV Status  
 
Infected  
 
250.60 
(207.08-
300.57) 
 
179.31 
(142.82-
222.28) 
 
43.21 (26.39-
66.73) 
 
30.24 (16.54-
50.75) 
 
116.66 
(87.64-
152.21) 
 
21.60 (10.36-
39.73) 
 
21.60 (10.36-
39.73) 
 
36.73 (21.39-
58.80) 
 
62.65 (41.96-
89.98) 
 
540.09 (475.21-
611.35) 
Uninfected 2.03 (1.43- 1.39 (0.91- 0.32 (0.12- 0.48 (0.22- 1.60 (1.08- 1.01 (0.61- 0.43 (0.18- 0.48 (0.22- 1.71 (1.17- 7.73 (6.52-9.10) 
23 
 
2.78) 2.03) 0.70) 0.91) 2.28) 1.58) 0.84) 0.91) 2.41) 
IRR (p-value) 123.70 
(<0.001) 
129.36 
(<0.001) 
135.08 
(<0.001) 
63.04 
(<0.001) 
72.94 
(<0.001) 
21.33 
(<0.001) 
50.65 
(<0.001) 
76.54 
(<0.001) 
36.72 
(<0.001) 
69.87  
(<0.001) 
Prematurity 
 
Term  
 
 
7.65 (6.43-
9.04) 
 
 
5.32 (4.31-
6.50) 
 
 
1.33 (0.85-
1.98) 
 
 
1.00 (0.59-
1.58) 
 
 
4.05 (3.17-
5.09) 
 
 
1.50 (0.99-
2.18) 
 
 
0.72 (0.38-
1.23) 
 
 
1.33 (0.85-
1.98) 
 
 
2.88 (2.15-
3.78) 
 
 
19.14 (17.17-
21.27) 
Preterm  12.63 (7.07-
20.83) 
10.11 (5.22-
17.65) 
1.68 (0.20-
6.08) 
4.21 (1.37-
9.83) 
9.26 (4.62-
16.57) 
1.68 (0.20-
6.08) 
4.21 (1.37-
9.83) 
1.68 (0.20-
6.08) 
7.58 (3.47-
14.39) 
41.26 (30.53-
54.55)  
IRR (p-value) 1.65 (0.080) 1.90 (0.051) 1.27 (0.698) 4.22 (0.014) 2.29 (0.020) 1.12 (0.808) 5.84 (0.004) 1.27 (0.698) 2.63 (0.016) 2.16 (<0.001) 
Study group  
 
HIV+PCV+ 
 
176.22 
(125.31-
240.90) 
 
122.00 (80.40-
177.50)  
 
45.18 (21.67-
83.10) 
 
27.11 (9.95-
59.01) 
 
99.41 (62.30-
150.50) 
 
31.63 (12.72-
65.17) 
 
31.63 (12.72-
65.17) 
 
27.11 (9.95-
59.00) 
 
58.74 (31.28-
100.45) 
 
451.85 (367.64-
549.57) 
HIV+PCV- 318.74 
(251.55-
398.37) 
231.81 
(175.11-
301.03) 
41.40 (19.85-
76.13) 
33.12 (14.30-
65.25) 
132.46 
(90.61-
187.00)  
12.42 (2.56-
36.29) 
12.42 (2.56-
36.29) 
45.53 (22.73-
81.47) 
66.23 (37.86-
107.56) 
620.93 (525.54-
728.62) 
IRR (p-value) 0.55 (0.002) 0.53 (0.005) 1.09 (0.847) 0.82 (0.724) 0.75 (0.303) 2.55 (0.179) 2.55 (0.179) 0.60 (0.316) 0.89 (0.754) 0.73 (0.013) 
HIV-PCV+ 1.70 (0.97-
2.77) 
0.85 (0.37-
1.68) 
0.53 (0.17-
1.24) 
0.53 (0.17-
1.25) 
1.17 (0.59-
2.10) 
1.28 (0.66-
2.24) 
0.75 (0.30-
1.54) 
0.64 (0.24-
1.39) 
1.38 (0.74-
2.37) 
7.45 (5.81-9.42) 
HIV-PCV- 2.35 (1.47-
3.56) 
1.92 (1.14-
3.04) 
0.11 (0.00-
0.59) 
0.43 (0.12-
1.09) 
2.02 (1.22-
3.16) 
 
0.75 (0.30-
1.54) 
0.11 (0.00-
0.59) 
0.32 (0.07-
0.93) 
2.03 (1.22-
3.17) 
8.01 (6.30-
10.04) 
IRR (p-value) 0.73 (0.332) 0.44 (0.051) 4.99 (0.126) 1.25 (0.757) 0.58 (0.147) 1.71 (0.266) 6.98 (0.039) 1.99 (0.346) 0.68 (0.293) 0.93 (0.667) 
Season  
 
Summer  
7.50 (5.87-
9.45) 
4.90 (3.60-
6.51)  
 
1.35 (0.72-
2.32)  
 
0.83 (0.36-
1.64) 
 
4.17 (2.98-
5.68) 
 
1.35 (0.72-
2.32) 
 
0.63 (0.23-
1.36) 
 
1.15 (0.57-
2.05) 
 
2.50 (1.60-
3.72) 
 
18.13 (15.54-
21.04)  
Winter  8.52 (6.78-
10.58) 
6.44 (4.94-
8.26)  
1.35 (0.72-
2.31)  
1.56 (0.87-
2.57) 
4.57 (3.32-
6.14) 
1.66 (0.95-
2.70)  
1.25 (0.64-
2.18)  
1.56 (0.87-
2.57) 
3.85 (2.71-
5.30) 
22.97 (20.04-
26.20)  
IRR (p-value)  1.14 (0.432) 1.32 (0.156) 1.00 (0.995) 1.87 (0.153) 1.10 (0.674) 1.23 (0.590) 1.99 (0.169) 1.36 (0.446) 1.54 (0.100) 1.27 (0.019) 
* PCV9 serotypes included: 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F as well as PCV9-related serotypes 6A, 19A and 19B; Vaccine-serotypes and non-vaccine serotypes do not add up to the total pneumococcal incidence as latex positive, culture 
negative S. pneumoniae cultures were not serotyped. 
** Other bacterial infections include: Streptococcus spp (n=11 ), P. aeruginosa (n=9), N. meningitidis (n=8), A. lwoffii (n=6) , Campylobacter spp (n=6), E. faecalis (n=6), C. albicans (n=3), Alcaligenes spp (n=2), M. morganii (n=2), M. tuberculosis 
(n=2), C. freundii (n=1), E. vulneris (n=1), non-typable H. influenzae (n=1), H. parainfluenzae (n=1), M. catarrhalis (n=1),  and S. flexneri (n=1) 
***Enrolment took place at 28-84 days old hence the <6 month group excludes children under 28 days  
Abbreviations: HIV-PCV- = HIV-uninfected placebo recipients; HIV-PCV+ = HIV-uninfected PCV9 recipients; HIV+PCV- = HIV-infected placebo recipients; HIV+PCV+ = HIV-infected PCV9 recipients; PCV9 = 9-valent pneumococcal conjugate vaccine. 
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There was an overall trend towards decreasing incidence of IBI with increasing age (Figure 3.3A). 
Participants under 6 months of age had the highest incidence of IBI as compared to other age 
groups. There was a sharp decline in incidence between the <6 months and 6-11 months age groups 
(IRR 2.20, p<0.001). Figure 3.3B shows the overall incidence of S. pneumoniae IBI stratified by PCV9 
serotypes (including PCV9-related) and non-PCV9 serotypes. Incidence of both PCV9 serotypes 
(including PCV9-related) and non-PCV9 serotypes decreased with increasing age.  
An analysis of the contaminants (Appendix: Table S1) revealed a high rate of contamination due to S. 
epidermidis (387.08; 95% CI, 359.76 to 415.93), which was responsible for 73.3% of total blood 
culture contamination. Other important contaminants in the cohort included Corynebacterium spp 
(which were responsible for 9.7% of total blood culture contamination with an incidence rate of 
48.39; 95% CI, 39.05 to 59.28) and Bacillus spp (which were responsible for 5.3% of total blood 
culture contamination with an incidence rate of 26.53; 95% CI, 19.76 to 34.89). The proportion of 
contaminated blood cultures (for all hospitalisations in the cohort) was similar between the HIV-
infected and HIV-uninfected participants (12.9% versus 12.3% respectively, p=0.467), however the 
incidence rates of contaminating organisms were significantly higher in HIV-infected participants 
(incidence rate of 678.35; 95% CI, 605.38 to 757.68) than in HIV-uninfected participants (incidence 
rate of 34.60; 95% CI, 31.99 to 37.37) indicated by an IRR of 19.61 (95% CI, 17.08 to 22.47, p<0.001). 
Vaccination with PCV9 had no significant effect on incidence of contaminants in either the HIV-
infected or HIV-uninfected participants. The incidence for HIV-infected PCV9 vaccinated participants 
was 700.36 (95% CI, 594.45 to 819.71) while for HIV-infected control participants incidence was 
658.18 (95% CI, 559.85 to 768.81) resulting in an IRR of 1.06 (95% CI, 0.85 to 1.34, p=0.582). The 
incidence for HIV-uninfected PCV9 vaccinated participants was 32.90 (95% CI, 29.33 to 36.78) while 
for HIV-uninfected control participants incidence was 36.30 (95% CI, 32.55 to 40.38) resulting in an 
IRR of 0.91 (95% CI, 0.77-1.06, p=0.201).  
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Figure 3.3: A) Incidence rates across age groups for different IBI pathogens. B)  Incidence rates across 
age groups for S. pneumoniae infections (separated into PCV9 serotypes* and non-PCV9 serotypes). 
* PCV9 serotypes included: 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F and PCV9-related serotypes (6A, 19A and 19B). 
Note: Enrolment took place at 28-84 days old hence the <6 month group excludes children under 28 days.  
 
Overall, males (incidence rate of 22.82; 95% CI, 19.90 to 26.04) had a higher incidence of IBI than 
females (incidence rate 18.27; 95% CI, 15.66 to 21.19) as indicated by a significant IRR of 1.25 (95% 
CI, 1.02 to 1.53, p=0.028). Stratification by bacterial pathogen indicated that this was a non-
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discriminatory, cumulative effect rather than being caused by any specific pathogen (i.e. no specific 
pathogen affected males significantly more than females; Table 3.2). A separate analysis of CoNS 
infections (Appendix – Table S4) indicated that males have a 34% higher odds of CoNS infections as 
compared to females (p<0.001).   
HIV-infected participants (incidence rate of 540.09; 95% CI, 475.21 to 611.35) had significantly 
higher incidence of IBI for all pathogens as compared to HIV-uninfected participants (incidence rate 
of 7.73; 95% CI, 6.52-9.10) with an IRR of 69.87 (95% CI, 56.71 to 86.33, p<0.001). The incidence for 
S. pneumoniae was higher in the HIV-infected (250.60; 95% CI, 207.08 to 300.57) compared to the 
HIV-uninfected participants (2.03; 95% CI, 1.43 to 2.78) with an IRR of 123.70 (95% CI, 85.09 to 
183.47, p<0.001).  
An analysis of seasonality indicated a slight increase in IBI incidence during winter. Incidence in 
summer was 18.13 (95% CI, 15.51 to 21.04) while incidence in winter was 22.97 (95% CI, 20.04 to 
26.20) resulting in an IRR of 1.27 (95% CI, 1.03 to 1.55, p=0.019). This was a cumulative effect rather 
than being due to an increase in any specific pathogen during winter (changes for all individual 
pathogens were non-significant; Table 3.2).    
3.2 Effect of PCV9 vaccination on IBI  
The overall IBI incidence rate was significantly lower for PCV9 vaccinated (17.68; 95% CI, 15.12 to 
20.55) versus control participants (23.42; 95% CI, 20.46 to 26.69) indicated by an IRR of 0.76 (95% CI, 
0.61 to 0.93, p=0.006). Incidence of S. pneumoniae was 5.72 (95% CI, 4.31 to 7.45) in the PCV9 
vaccinated participants as compared to 10.31 (95% CI, 8.38 to 12.55) in the control group (IRR=0.56; 
95% CI, 0.39 to 0.78, p<0.001). This decrease in S. pneumoniae incidence in the vaccinated group 
was due to the significant decrease in incidence of PCV9- and PCV9-related serotypes. Incidence in 
PCV9 vaccinated was 3.64 (95% CI, 2.54 to 5.06) while incidence in control participants was 7.70 
(95% CI, 6.05 to 9.67) resulting in an IRR of 0.47 (95% CI, 0.30 to 0.71, p<0.001). There was no 
significant overall change in incidence of non-PCV9 serotypes due to vaccination. Incidence in PCV9 
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vaccinated was 1.56 (95% CI, 0.87 to 2.57) while incidence in control group was 1.15 (95% CI, 0.57 to 
2.05) resulting in an IRR of 1.36 (95% CI, 0.59 to 3.28, p=0.443). The vaccinated group showed a 
significant increase in incidence of Klebsiella spp. Incidence in PCV9 vaccinated was 1.46 (95% CI, 
0.80 to 2.44) versus 0.42 (95% CI, 0.11 to 1.07) in the control group resulting in an IRR of 3.50 (95% 
CI, 1.10 to 14.59, p=0.019). There was a trend towards decrease in E. coli in the PCV9 vaccinated 
group which had an incidence of 1.14 (95% CI, 0.57 to 2.05) versus 5.31 (95% CI, 3.95 to 6.98) in the 
control group resulting in an IRR of 0.65 ((95% CI, 0.40 to 1.02, p=0.050); Table 3.2).   
Figure 3.4: The proportions of pathogens detected in IBI events by study group (HIV and PCV9 
vaccination status)  
Abbreviations: Hib = H. influenzae type b; HIV-PCV- = HIV-uninfected placebo recipients; HIV-PCV+ = HIV-uninfected PCV9 
recipients; HIV+PCV- = HIV-infected placebo recipients; HIV+PCV+ = HIV-infected PCV9 recipients. 
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3.2.1 HIV-uninfected participants 
Streptococcus pneumoniae was the leading cause of IBI in both the HIV-infected and HIV-uninfected 
participants, despite vaccination (i.e. S. pneumoniae still had the highest incidence in the vaccinated 
group compared to other pathogens). Incidence rates indicate that vaccination in HIV-uninfected 
participants had no overall effect in reducing all-cause IBI hospitalisations, with incidence of 7.45 
(95% CI, 5.81 to 9.42) in the PCV9 vaccinated and 8.01 (95% CI, 6.30 to 10.04) in the control group 
and a resulting IRR of 0.93 (95% CI, 0.66 to 1.31, p=0.667). There was no reduction in S. pneumoniae 
infections, with incidence of 1.70 (95% CI, 0.97 to 2.77) in the PCV9 vaccinated and 2.35 (95% CI, 
1.47 to 3.56) in the control group, resulting in an IRR of 0.73 (95% CI, 0.36 to 1.45, p=0.332). There 
was a decrease in incidence of PCV9- and PCV9-related serotype IBI events (IRR=0.44; 95% CI, 0.17 to 
1.07, p=0.051) in vaccinated (0.85; 95% CI, 0.37 to 1.68) compared to unvaccinated (1.92; 95% CI, 
1.14 to 3.04) HIV-uninfected participants. There was no significant change in incidence of non-PCV9 
vaccine serotype IBI events between vaccinated (0.53; 95% CI, 0.17 to 1.24) and unvaccinated (0.11; 
95% CI, 0.00 to 0.59) HIV-uninfected children, indicated by an IRR of 4.99 (95% CI, 0.56 to 235.81, 
p=0.126). Vaccination in the HIV-uninfected participants was associated with a significant increase in 
Klebsiella spp IBI, with an incidence of 0.75 (95% CI, 0.30 to 1.54) in the PCV9 vaccinated and 0.11 
(95% CI, 0.00 to 0.59) in the control group and a resulting significant IRR of 6.98 (95% CI, 0.90 to 
314.58, p=0.039).  This study was underpowered (<80.00% power) to determine a significant 
difference in incidence in the HIV-uninfected group between PCV9 and placebo vaccinated 
participants as the differences between the groups were small.  
3.2.2 HIV-infected participants 
Receipt of PCV9 in the HIV-infected group was associated with a decrease in S. pneumoniae 
incidence and an increase in the proportion of infections due to Klebsiella spp and Salmonella spp, 
however the proportions of most pathogens remained largely unchanged (Figure 3.4). Incidence 
rates (Table 3.2) indicated that there was a significant reduction in overall IBI in the vaccinated HIV-
infected participants (incidence of 451.85; 95% CI, 367.64 to 549.57) compared to unvaccinated HIV-
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infected participants (incidence of 620.93; 95% CI, 525.54 to 728.62) indicated by a significant IRR of 
0.73 (95% CI, 0.56 to 0.94, p=0.013). This reduction was specifically caused by the large reduction in 
S. pneumoniae incidence (with incidence of 176.22 (95% CI, 125.31 to 240.90) in the PCV9 
vaccinated and 318.74 (95% CI, 251.55 to 398.37) in the control group) indicated by a significant IRR 
of 0.47 (95% CI, 0.30 to 0.71, p=0.002). In particular, reduction in S. pneumoniae incidence was due 
to the reduction in PCV9- and PCV9-related serotype infections (with incidence of 122.00 (95% CI, 
80.40 to 177.50) in the PCV9 vaccinated and 231.81 (95% CI, 175.11 to 301.03) in the control group) 
indicated by a significant IRR of 0.53 (95% CI, 0.32 to 0.85, p=0.005). There was no significant change 
in IBI due to non-PCV9 serotypes between vaccinated (45.18; 95% CI, 21.67 to 83.10) and placebo 
participants (41.40; 95% CI, 19.85 to 76.13) with an IRR of 1.09 (95% CI, 0.41 to 2.92, p=0.847). This 
study was well powered to determine the differences in incidence seen between the PCV9 and 
placebo vaccinated participants in the HIV-infected groups (89.96% power to determine the 
difference in S. pneumoniae incidence, 79.31% power to determine the difference in overall IBI 
incidence and 82.89% power to determine the difference in incidence of PCV9- and PCV9-related 
serotypes).  
3.2.3 Description of IBI in CSF  
In the analysis of CSF isolates observed in the study cohort, the proportions of S. pneumoniae were 
reduced in the vaccinated group compared to the placebo group for both the HIV-infected and HIV-
uninfected participants (although IRRs were non-significant for both, p=0.19 and p=0.21 
respectively). The proportion of CSF infections due to S. pneumoniae (51.6%; 95% CI, 41.5 to 61.8%) 
was significantly higher (p=0.026) than the proportion in blood infections (38.9%; 95% CI, 34.2 to 
43.8%) (Appendix Figure S2 and Table S6).   
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3.2.4 Description of ‘other’ IBI group  
A description of the ‘other’ group is given in the Appendix (Figure S1). This demonstrates that Gram 
negatives constituted the largest proportion of this group and that their proportion increased in the 
PCV9 vaccinated group. Mycobacterium tuberculosis and fungal (C. albicans) infections were only 
found in the placebo groups, although the numbers were too small to make conclusive statements 
regarding the significance of these findings.  
3.3 Risk factors of IBI  
After controlling for sex and prematurity, only receipt of PCV9 and HIV status retained significance in 
the model which was used to determine risk factors for IBI in the study cohort (Table 3.3). The odds 
of IBI hospitalisation among PCV9 vaccinated participants was 21.00% (95% CI, 2.60 to 35.40%) lower 
than the odds among unvaccinated participants. The odds of hospitalisation with IBI among HIV-
infected participants was 25.85 (95% CI, 20.93 to 31.91) times greater than the odds for HIV-
uninfected participants. Prematurity was a significant risk factor in the univariate analysis, but in the 
multivariate analysis it did not retain significance (p=0.629) (Table 3.3). 
Table 3.3: Risk factors associated with IBI hospitalisation 
 Univariate  Multivariate * 
OR (95% CI) P-value OR (95% CI)  P-value 
Vaccination  
Control  
 
Ref  
 
- 
 
Ref 
 
- 
PCV9 0.75 (0.62-0.92)  0.005 0.79 (0.65-0.97) 0.027 
Sex 
Female  
 
Ref  
 
- 
 
Ref 
 
- 
Male  1.22 (0.99-1.48) 0.052 1.12 (0.91-1.37) 0.278 
HIV 
Uninfected  
 
Ref  
 
- 
 
Ref 
 
- 
Infected 25.90 (21.07-31.95) <0.001 25.85 (20.93-31.91)  <0.001 
Prematurity 
Term  
 
Ref  
 
- 
 
Ref 
 
- 
Preterm 1.77 (1.31-2.39) <0.001 0.93 (0.68-1.27) 0.629 
* Adjusted for PCV9 vaccination, sex, HIV status and prematurity.  
Abbreviations: OR = odds ratio; PCV9 = 9-valent pneumococcal conjugate vaccine; Ref = referent. 
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A separate analysis of CoNS IBI was conducted (Appendix: Table S4) to determine which risk factors 
were important for infection with this pathogen. The multivariate analysis indicated that male sex 
(OR = 1.34; 95% CI, 1.15 to 1.55, p<0.001), HIV infection (OR = 7.07; 95% CI, 6.04 to 8.28, p<0.001) 
and preterm birth (OR = 2.06; 95% CI, 1.69 to 2.50, p<0.001) were risk factors for isolation of CoNS in 
blood cultures. When this analysis was restricted to events in participants under 3 months of age 
only (Appendix: Table S5), it was found that HIV (OR = 6.80; 95% CI, 4.72-9.79, p<0.001) and preterm 
birth (OR = 2.17; 95% CI, 1.40-3.36, p<0.001) were risk factors for isolation of CoNS in blood cultures.  
3.4 Clinical Characteristics  
In terms of clinical presentation of IBI infections, E. coli (p<0.001), S. aureus (p<0.001), Klebsiella spp 
(p<0.001) and ‘other’ (p<0.001) were significantly less likely to be associated with fever as compared 
to infections with S. pneumoniae. IBI caused by S. aureus was associated with refusal to eat 
(p=0.018). Escherichia coli infections were associated with vomiting (p=0.004). Escherichia coli 
(p=0.002) and Salmonella spp (p=0.044) were significantly associated with diarrhoea. There was no 
association between type of bacterial pathogen and weight-loss (p=0.170), night sweats (p=0.326), 
seizures (p=0.159) or excessive crying (p=0.937).  
3.5 Outcomes of IBI  
3.5.1 Severity Indicator: Death versus Survival 
The odds of severe outcome (death) decreased with increasing age (Table 3.4). The odds of dying for 
HIV-infected participants were 4.60 (95% CI, 2.38 to 8.89) times the odds for HIV-uninfected 
participants (p<0.001). Klebsiella spp, E. coli, Hib and ‘other’ showed a trend towards increased odds 
of death compared to S. pneumoniae (although not significant in the analysis). Staphylococcus 
aureus IBI was associated with a trend towards reduced odds of death compared to S. pneumoniae 
(although not significant). There was no significant change in odds of death for PCV9 vaccinated 
versus placebo groups in either HIV-infected (p=0.522) or HIV-uninfected (p=0.141) participants. 
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History of having been born prematurely was not associated with an increased odds of death 
(p=0.204) (Table 3.4).  
Table 3.4: Predictors of poor outcome (death) for participants hospitalised with IBI 
 Univariate  Multivariate * 
OR  P-value OR  P-value 
Bacteria type 
S. pneumoniae  
 
Ref 
 
- 
 
Ref 
 
- 
Hib 1.52 (0.55-4.20)  0.427 1.57 (0.52-4.72)  0.423 
E. coli  1.93 (1.05-3.57)  0.038 1.79 (0.91-3.51)  0.092 
S. aureus  0.50 (0.14-1.76)  0.272 0.58 (0.15-2.34)  0.432 
Klebsiella spp 2.16 (0.75-6.22)  0.160 2.36 (0.72-7.77)  0.156 
Salmonella spp 1 -**  1 -**  
Other 1.06 (0.50-2.23)  0.904 1.18 (0.52-2.70) 0.690 
HIV  
Uninfected 
 
Ref 
 
- 
 
Ref 
 
- 
Infected 3.17 (1.74-5.80)  <0.001 4.60 (2.38-8.89)  <0.001 
Age category  
1-5 months 
 
Ref 
 
- 
 
Ref 
 
- 
6-11 months 1.35 (0.75-2.44)  0.323 1.05 (0.54-2.03)  0.885 
12-17 months 0.54 (0.23-1.24)  0.146 0.42 (0.17-1.04)  0.062 
18-23 months 0.23 (0.05-1.00)  0.050 0.22 (0.05-1.01)  0.051 
24-35 months 0.29 (0.10-0.86)  0.025 0.16 (0.05-0.51)  0.002 
36-59 months 0.40 (0.15-1.09) 0.073 0.25 (0.08-0.72)  0.011 
Sex 
Female 
 
Ref 
 
- 
 
Ref 
 
- 
Male 0.90 (0.55-1.47)  0.677 0.82 (0.48-1.41)  0.474 
Vaccination 
Placebo 
 
Ref 
 
- 
 
Ref 
 
- 
PCV9 1.26 (0.77-2.05)  0.353 1.57 (0.90-2.74)  0.112 
Prematurity 
Term  
 
Ref 
 
- 
 
Ref 
 
- 
Preterm 0.71 (0.32-1.59)  0.410 0.57 (0.24-1.36)  0.204 
* Adjusted for bacterial type, HIV infection, age category, sex, PCV9 vaccination and prematurity.  
**All participants infected with Salmonella survived (outcome did not differ) and hence could not be modelled.  
Abbreviations: Hib = H. influenzae type b; OR = odds ratio; PCV9 = 9-valent pneumococcal conjugate vaccine; Ref = 
referent. 
3.5.2 Severity Indicator: Prolonged Hospitalisation (>4 days versus ≤4 days) 
As shown in the multivariate analysis, HIV-infected participants had significantly higher odds of being 
hospitalised for longer than 4 days as compared to HIV-uninfected participants (p=0.042). There was 
a trend towards higher odds for longer hospital stay for participants hospitalised with E. coli, S. 
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aureus, Klebsiella spp and ‘other’ as compared to S. pneumoniae (however this was not significant) 
(Table 3.5). There was a trend towards higher odds for shorter hospital stay for Hib and Salmonella 
spp as compared to S. pneumoniae (although not significant). Odds of longer hospitalisations did not 
change for preterm versus term babies (p=0.436) (Table 3.5).   
Table 3.5: Predictors of prolonged hospitalisation (>4 days) for participants hospitalised with IBI 
 Univariate Multivariate*  
OR  P-value OR  P-value 
Bacteria type 
S. pneumoniae  
 
Ref 
 
- 
 
Ref 
 
- 
Hib 0.72 (0.30-1.72)  0.456 0.80 (0.33-2.00)  0.633 
E. coli  1.31 (0.75-2.29) 0.339 1.48 (0.83-2.64)  0.188 
S. aureus  0.93 (0.41-2.08) 0.858 1.09 (0.46-2.54)  0.848 
Klebsiella spp 1.31 (0.47-3.68)  0.606 1.34 (0.45-3.93)  0.598 
Salmonella spp 0.66 (0.28-1.51) 0.322 0.70 (0.30-1.67)  0.427 
Other 1.34 (0.72-2.51)  0.353 1.53 (0.80-2.93)  0.202 
HIV  
Uninfected 
 
Ref 
 
- 
 
Ref 
 
- 
Infected 1.48 (0.97-2.25)  0.066 1.61 (1.02-2.56)  0.042 
Age category  
1-5 months 
 
Ref 
 
- 
 
Ref 
 
- 
6-11 months 0.63 (0.37-1.09)  0.101 0.63 (0.36-1.11)  0.107 
12-17 months 0.92 (0.48-1.78)  0.814 0.89 (0.45-1.75)  0.734 
18-23 months 1.22 (0.51-2.89)  0.652 1.34 (0.56-3.25)  0.513 
24-35 months 1.16 (0.57-2.34)  0.689 1.08 (0.51-2.27)  0.845 
36-59 months 1.16 (0.56-2.39)  0.697 1.08 (0.50-2.34)  0.851 
Sex 
Female 
 
Ref 
 
- 
 
Ref 
 
- 
Male 1.10 (0.73-1.65)  0.661 1.04 (0.68-1.58)  0.863 
Vaccination 
Placebo 
 
Ref 
 
- 
 
Ref 
 
- 
PCV9  1.14 (0.76-1.72)  0.532 1.13 (0.73-1.74)  0.603 
Prematurity 
Term  
 
Ref 
 
- 
 
Ref 
 
- 
Preterm  1.33 (0.70-2.50)  0.384 1.30 (0.67-2.53)  0.436 
* Adjusted for bacterial type, HIV infection, age category, sex, PCV9 vaccination and prematurity.  
Abbreviations: Hib = H. influenzae type b; OR = odds ratio; PCV9 = 9-valent pneumococcal conjugate vaccine; Ref = 
referent. 
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3.6 Description of Klebsiella spp IBI in the cohort  
 
The incidence of Klebsiella spp was shown to be significantly increased in PCV9 vaccinated 
participants (Table 3.2). This was further investigated to determine which risk factors were 
associated with invasive Klebsiella spp. Table 3.6 indicates that HIV infection (OR= 15.49; 95% CI, 
5.98 to 40.12, p<0.001), preterm birth (OR=2.96; 95% CI, 1.03 to 8.53, p=0.044) and PCV9 
vaccination (OR=3.83; 95% CI, 1.26 to 11.65, p=0.018) are significantly associated with Klebsiella spp 
IBI.  
Table 3.6: Risk factors associated with invasive Klebsiella spp infection 
 Univariate  Multivariate * 
OR  P-value OR  P-value 
Vaccination  
Control  
 
Ref  
 
- 
 
Ref 
 
- 
PCV9 3.52 (1.16-10.69)  0.027 3.83 (1.26-11.65)  0.018 
Sex 
Female  
 
Ref  
 
- 
 
Ref 
 
- 
Male  1.20 (0.47-3.05)  0.697 1.09 (0.43-2.78)  0.850 
HIV 
Uninfected  
 
Ref  
 
- 
 
Ref 
 
- 
Infected 17.34 (6.84-43.96)  <0.001 15.49 (5.98-40.12)  <0.001 
Prematurity 
Term  
 
Ref  
 
- 
 
Ref 
 
- 
Preterm 4.75 (1.69-13.35)  0.003 2.96 (1.03-8.53)  0.044 
* Adjusted for PCV9 vaccination, sex, HIV infection and prematurity.  
Abbreviations: OR = odds ratio; PCV9 = 9-valent pneumococcal conjugate vaccine; Ref = referent. 
The 18 invasive Klebsiella spp infections included in the analysis were spread out over a period of 4 
years with 9 events occurring in 1999, 4 events occurring in 2000, 3 events occurring in 2001 and 2 in 
2002. Even though there were more events in 1999 than any other year, there were no more than 2 
events per month. It is thus unlikely that these infections constituted an outbreak. None of the 18 
participants hospitalised with Klebsiella spp infections had recorded previous hospitalisations and 
hence these infections were unlikely to be nosocomial in nature. Half of the Klebsiella spp infections 
(n=9) occurred in participants under the age of 6 months and only one event was in a child under the 
age of 3 months. 
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4. Chapter Four: Discussion  
Streptococcus pneumoniae and E. coli were found to be the commonest causes of IBI hospitalisations 
in this cohort. This chapter will start by exploring some of the possible reasons for incidence rates 
being higher in the current cohort than those that have been reported in other settings. HIV-infected 
participants had significantly higher incidence rates for all causative pathogens, however PCV9 was 
shown to be effective in reducing overall IBI incidence in this high risk group. Vaccination was shown 
to significantly reduce incidence of PCV9- and PCV9-related serotypes in HIV-infected participants 
with marginally significant reductions in the HIV-uninfected participants. The main risk factors for IBI 
hospitalisation were found to be HIV infection and non-receipt of PCV9. There was however, an 
increase in hospitalisations due to Klebsiella spp in the PCV9 vaccinated participants. The context of 
these findings in terms of existing literature is discussed in this chapter.   
4.1 Description of IBI in the cohort  
This analysis estimated overall IBI incidence rates of 20.55 (95% CI, 18.57 to 22.68) per 10 000 
person-years, with invasive S. pneumoniae incidence rates of 8.01 (95% CI, 6.80 to 9.38) per             
10 000 person-years in a South African cohort under-5 years of age during an important efficacy trial 
of PCV9 (1998 through 2005). Greenhow et al (2017) reported IBI rates of 9.70 (95% CI, 79.40 to 
11.70) per 10 000 person-years and invasive S. pneumoniae  incidence rates of 7.45 (95% CI, 5.90 to 
9.30) per 10 000 person-years in the pre-PCV era in California, United States (41). These rates 
declined to 2.90 (95% CI, 2.04 to 3.89) and 1.00 (95% CI, 0.50 to 1.80), respectively, post-PCV 
introduction. Incidence rates were estimated from otherwise healthy, full-term children and as such 
are expected to be significantly lower than for the current study setting with a high HIV prevalence.  
IBI incidence rates observed in this study confirm the large burden of infectious disease in Africa as 
opposed to those seen in higher income settings. The American study demonstrated a very different 
age distribution compared to the current study. In the American study there was a spike in invasive 
S. pneumoniae in the 12-18 month age group (pre-PCV era). In the era post-introduction of PCV this 
36 
 
age-related incidence spike was not appreciated, however the overall pattern of decreasing IBI 
incidence with increasing age (as evident in the current study) was still not seen. This likely 
represents differences in community-acquired infections between settings. In high income countries 
children are more likely to be exposed to pathogens later on when they go to nursery school or day 
care, whereas in a middle or low income setting children are likely to be exposed to pathogens at an 
earlier age (possibly as a result of the pathogen concentration effect of larger households, including 
lack of sanitation and communal living which would be expected to enhance carriage and 
transmission of organisms between family members) (5, 42). In low income settings, younger 
children may also be at higher risk of malnutrition compared to older children that are more readily 
able to fend for themselves. Middle and low income settings would also experience higher rates of 
intrinsic factors such as malnutrition and immunodeficiency (due to higher rates of HIV and 
malnutrition) which may impact on the ability to suppress overgrowth of colonising pathogens, 
especially in young children with developing immune systems.    
Male children were found to have higher incidence rates of IBI overall as compared to female 
children, which corroborates findings from other studies. A study in Korea demonstrated that male 
children are 1.4 times as likely to be hospitalised with IBI than females of the same age (2). It has 
been found that males have overall higher morbidity and mortality compared to females due to their 
increased susceptibility to and severity of disease (43). One theory for this is that females are able to 
mount a stronger humoral and cellular immune response and hence have increased protection 
against certain pathogens (reducing carriage and increasing clearance) (43). Females have also been 
shown to have increased antibody titres post-vaccination with measles vaccine (among others) as 
compared to males (43). In the current study, this difference between the sexes was particularly 
illustrated in the analysis of CoNS IBI which showed that males were significantly more likely to be 
hospitalised with CoNS bacteraemia as compared to females. The clinical relevance of CoNS, and 
specifically S. epidermidis, infections however is debatable and is discussed in further detail below.  
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The incidence of IBI in HIV-infected children was nearly 70 times greater than that of HIV-uninfected 
children (p<0.001). Almost two thirds (63.3%) of the IBI events occurred in HIV-infected participants, 
despite HIV-infected participants constituting only 3.2% of the total cohort. This proportion is in line 
with previous findings in South Africa which estimate that 70.0% of IPD occurs in HIV-infected 
children, while  the estimated HIV-infected population of children make up <5.0% of the total 
population (in 2008) (36). With increased access to ART and improved PMTCT, the burden of 
infectious disease in association with HIV infection is likely to continue to decrease. There is still 
however, a large population of HIV-exposed children who, despite being HIV-uninfected, is at an 
increased risk for being hospitalised with IBI (44).  
An analysis of contamination indicated that the proportion of contaminated blood cultures (for all 
hospitalisations in the cohort) was similar between the HIV-infected and HIV-uninfected participants, 
however, the incidence of contaminants was significantly higher in HIV-infected participants 
compared to HIV-uninfected participants. This could be because HIV-infected children are more 
susceptible to infections (which may or may not be clinically relevant); alternatively, it could be a 
result of bias due to the fact that the proportion of HIV-infected children that were hospitalised was 
much higher than the proportion of HIV-uninfected children that were hospitalised and hence more 
blood samples were taken, which would result in more contamination events.  
Escherichia coli was the second leading cause of IBI (after S. pneumoniae) in all study groups. This 
indicates that besides being one of the leading causes for diarrhoea-associated morbidity and 
mortality in infants and children, the role of E. coli  in IBI should not be underestimated (45). A study 
from Ghana reported the proportion of bloodstream infections caused by E. coli  to be around 8.1% 
(46). This estimation is lower than the current study in which 21.3% of all bloodstream infections 
were caused by E. coli. The high E. coli incidence highlights the need for improvements in 
infrastructure in terms of access to clean water and sanitation in the present community.   
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4.2 The Effect of PCV9 Vaccination on IBI  
PCV9 vaccination significantly reduced all-cause IBI incidence rates in the cohort. This reduction was 
primarily due to the reduction in incidence of S. pneumoniae. When stratified by serotype, it was 
shown that the reduction in S. pneumoniae was a result of the significant decrease in infections due 
to PCV9- and PCV9-related serotypes. There was no overall change in incidence of non-PCV9 
serotypes between vaccinated and placebo recipients.  
Incidence rates were still relatively high for S. pneumoniae in the vaccinated participants (5.72; 95% 
CI, 4.31 to 7.45 per 10 000 person-years) as compared to reported rates from high income settings 
(1.0; 95% CI, 0.50 to 1.80 per 10 000 person-years) (41). Additional pneumococcal serotypes 
(specifically 3, 6A, 7F and 19A) were included in the PCV vaccine with the introduction of PCV13 to 
the EPI-SA in 2011 (47). The current analysis indicated that there was already a significant decrease 
in the PCV13 serotypes (IRR=0.46; 95% CI, 0.21 to 0.95, p=0.024) with PCV9 vaccination. This was 
largely due to the decrease in serotype 19A in the PCV9 vaccinated children. It is important to note 
that PCV9 was never licensed or introduced into the EPI-SA, instead, PCV7 was licensed and was 
introduced into in 2009 (34). PCV7 was trialled extensively in developed countries while trials in 
developing countries focussed mainly on PCV9. Since PCV9 and PCV7 are closely related, the efficacy 
studies for PCV9 were used to project the performance of PCV7 in terms of immunogenicity and 
safety (48). Studies suggested that lower valent formulations (such as PCV7, which contains antigens 
present in serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) have similar or higher efficacy as compared to 
higher valent formulations (such as PCV9, which contains serotypes 1 and 5 in addition to the PCV7 
serotypes) for serotypes included in both vaccines (48). As such, the efficacy estimated in the PCV9 
trials are hypothesised to be conservative estimates of the performance of PCV7 in reducing invasive 
disease (48). PCV7 does not include serotypes 1 or 5, however in the current analysis there was no 
significant reduction of these serotypes due to PCV9 vaccination (IRR for serotype 1 was 0.20; 95% 
CI, 0.01 to 1.79, p=0.125; IRR for serotype 5 was 0.00; 95% CI, 0.00 to 5.32, p=0.250). The incidence 
of serotypes 1 and 5 reported here, were however very low, supporting the introduction of PCV7. 
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Other reports have suggested that serotypes 1 and 5 constitute 15-20% of IPD in Africa, and hence 
vaccination with PCV7 may be less effective than vaccination with PCV9 in those settings (36).  
4.2.1 HIV-uninfected participants 
In the HIV-uninfected group there was no overall reduction in all-cause IBI associated with PCV9-
vaccination, and S. pneumoniae incidence was not reduced. The incidence of PCV9- and PCV9-
related serotypes was reduced by vaccination, however there was a trend towards an increase in 
non-PCV9 serotypes which diluted the overall effect of vaccination. It should be noted however, that 
the IBI incidence was very low in the HIV-uninfected placebo recipients and as such the number of 
events were too small to determine a significant change due to vaccination. These results are in 
keeping with the original analysis (which included approximately 2 years of follow up of participants 
as opposed to 5 years in the current analysis) which showed that PCV9 vaccination was significantly 
associated with a reduction in vaccine serotype IPD in HIV-uninfected children, however due to the 
increase in non-vaccine serotype IPD, there was no decrease in overall IPD (33).  
4.2.2 HIV-infected participants 
In the HIV-infected group, receipt of PCV9 was associated with a significant overall IBI reduction. This 
reduction was due to a decrease in incidence of S. pneumoniae IBI, specifically due to the significant 
decrease in PCV9- and PCV9-related serotypes (Appendix Table S3). This group showed reductions in 
incidence of IBI due to serotype 6A (IRR=0.24; 95% CI, 0.06 to 0.74, p=0.005), for which antigens are 
not included in the PCV9 vaccine. This protection against serotype 6A due to PCV vaccination has 
been documented and is due to immunological similarities with serotype 6B which allows some 
cross-reactivity (49). Cross-reactivity between 19A and 19B with the vaccine serotype, 19F, has also 
been reported. In the current study there was a decrease in incidence of 19A, however this was not 
significant (p=0.412). There was also no change in incidence of serotype 19B (p=0.522). Serotypes 
6A, 19A and 19B were included as PCV9-related serotypes in the analysis. A reduction in non-vaccine 
serotypes in HIV-infected children has been reported elsewhere due to improved care for children 
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exposed to or infected with HIV (access to co-trimoxazole preventive therapy, ART, PMTCT) (34). 
This is however, not relevant to the current analysis as the randomised design of the study would 
ensure that treatment of HIV-infected children in the PCV9 and in the control groups were 
consistent. The data analysed were collected in the pre-ART era and hence ART and PMTCT were not 
considered as confounders in this analysis. A decrease in vaccine serotype and non-vaccine serotype 
IBI would however, be expected over time with improved HIV treatment (34). The original analysis 
also reported a significant decrease in vaccine serotype IPD as well as reductions in overall IPD in 
HIV-infected children as seen here (33).   
4.2.3 Replacement disease in the cohort  
As previously discussed, the HIV-uninfected participants showed no change in overall incidence of S. 
pneumoniae as the reduction in PCV9- and PCV9-related serotypes was countered by an increase in 
IBI due to non-PCV9 serotypes. This could be due to replacement disease (36). Replacement disease 
arises when vaccine-serotypes are eliminated or reduced due to vaccination, thereby creating a 
biological niche which is then open to be filled by non-vaccine serotypes. Although vaccination is one 
of the largest drivers of replacement disease, antibiotic use and resistance also influence which 
serotypes are increased (50). It is unclear why there was a trend towards serotype replacement in 
the HIV-uninfected participants but not in the HIV-infected participants in the current study. One 
possible explanation is that vaccination significantly reduced the incidence of PCV9 serotypes in HIV-
infected participants however, there were still too many PCV9 serotype IBI events for replacement 
to occur. Another possible explanation for this observation is that the co-trimoxazole prophylaxis 
given to HIV-infected patients may have offered a protective advantage from colonisation with 
replacement serotypes.  
There was a significant increase in Klebsiella spp in the HIV-uninfected, vaccinated group which may 
also have been a result of replacement. Klebsiella spp are reported to be mainly hospital-acquired 
(95% of cases) and are usually associated with intravenous infusions for more than 3 days (51).  
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The birth cohort in Soweto in the year 2000 was estimate to be 24 000 (approximately 2 000 babies 
born per month) (30). Since enrolment took place over 32 months, it is estimated that 64 000 babies 
were born during this period. This translates into approximately 31% of the birth cohort in Soweto 
being vaccinated with PCV9 during the study period. It is hence noted that approximately one third 
of the Soweto birth cohort was vaccinated in the RCT and therefore there would have been minimal 
impact on the overall bacterial population (compared to what would be expected in populations 
with high vaccine coverage). The replacement disease reported here is hence an indication of trend 
only, since the study design was not designed to detect the long-term impact of replacement and is 
not powered to detect replacement disease (50).  
4.3 Risk Factors of IBI 
The analysis indicated that non-receipt of PCV9 and HIV infection were significant risk factors for IBI 
hospitalisation. As previously discussed, the reduction in IBI hospitalisation in PCV9 vaccinated 
participants was specific to the HIV-infected group. Preterm delivery was a significant predictor of IBI 
hospitalisation in univariate analyses, however in multivariate analyses it was no longer significant. 
This could be explained by the fact that HIV infection has been shown to be a risk factor for preterm 
delivery (52). A study done in urban KwaZulu-Natal in a cohort with high HIV prevalence, 
demonstrated that the odds of preterm delivery for HIV-infected women were 4.09 (95% CI, 1.37 to 
12.17, p=0.01) times the odds for HIV-uninfected women after controlling for multiple factors (52). 
The incidence rates reported here however, indicate that preterm infants experienced 2.16 times 
the number of IBI hospitalisations compared to full-term infants (p<0.001).  
4.3.1 Risk factors for Coagulase-negative staphylococcus infections  
Coagulase-negative staphylococcus was regarded as a contaminant for the purpose of this analysis, 
however literature indicates that this group of organisms (specifically S. epidermidis) may by 
pathogenic in certain clinical settings (40).  The analysis of CoNS IBI demonstrated that male sex, HIV 
infection and preterm birth were risk factors for CoNS infections. In young infants (under 3 months 
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of age), in whom CoNS was likely to be a clinically significant infection, HIV infection and preterm 
birth were significant risk factors. Despite S. epidermidis formerly being thought of as a skin 
commensal microorganism, it is becoming clearer that this microorganism may be an important 
opportunistic pathogen responsible for a large number of nosocomial infections (40). One of the 
main sources of infection for this pathogen is from indwelling medical devices (40). Invasive S. 
epidermidis infection is difficult to treat due to high levels of antibiotic resistance, and resistance to 
host defences through slime production which results in persistent colonisation (40). The incidence 
rate of CoNS in premature children under 3 months of age in the current cohort was 12.12 (95% CI, 
10.62 to 13.78) per 10 000 person years. It is likely that the infections were clinically significant in at 
least a proportion of these high risk children and would have required targeted antibiotic therapy. It 
is a limitation that no data on clinical and laboratory indicators to decide whether these were true 
nosocomial infections were available in this cohort. 
4.4 Clinical Characteristics  
Escherichia coli infections in the cohort had distinct clinical characteristics (including association with 
vomiting and diarrhoea, and being less likely to present with fever) as compared to S. pneumoniae 
IBI. Escherichia coli is associated with gastrointestinal tract infections and as such, cases are likely to 
present with diarrhoea and vomiting (53). Salmonella spp infections in the cohort were associated 
with diarrhoea. This has been well documented in literature, in which Salmonella spp cause 
enterocolitis which in turn leads to diarrhoea (54). The resulting enterocolitis is generally self-
limiting however, it is estimated to lead to bloodstream infections in approximately 6% of cases (54). 
In this cohort, infections with Klebsiella spp and other IBI were less likely to present with fever as 
compared to S. pneumoniae.  Infections with S. aureus were associated with refusal to eat and a 
lower prevalence of fever. Assessment of clinical characteristics associated with IBI was not a specific 
objective of the study and, as such, a detailed discussion of clinical characteristics has not been 
included.  
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4.5 Outcomes of IBI 
Although clinical characteristics differ somewhat between pathogens, the type of bacterial pathogen 
does not have much of an effect on severity of outcome (in terms of length of hospital stay as well as 
mortality). A study of IBI in Korean children under the age of 5 years (1996-2005) has shown N.  
meningitidis to have the highest case fatality rate (15.4%) although the incidence of this pathogen 
was very low (2). The current study also had very few cases of N. meningitidis (n=8), however all 8 
cases were reported to have survived the infection and hence the case fatality rate was much lower 
than expected from literature. The Korean study reported S. pneumoniae (12.4%) and GBS (10.4%) 
as having the most severe clinical outcomes (in terms of fatality rates) while H. influenzae (no 
fatalities), S. aureus (3.0%) and Salmonella spp (1.4%) were reported to be the least severe (2). Since 
GBS infection most commonly occurs in the neonatal period and this analysis only included 
surveillance of children beyond the neonatal period, very few GBS infections were noted (5). The 
Active Bacterial Core surveillance study based in the United States (1998-1999) reported a different 
case fatality pattern (although this study was population based and looked at patients of all ages). 
They found H. influenzae (13.9%) to have the highest case fatality rate followed by N. meningitidis 
(13.7%) (5). The current analysis did not find a significant difference in severity of outcome between 
bacterial pathogens.  
There are other risk factors that increased severity of disease. These included age (poorer outcomes 
expected with younger age) and HIV infection. This is in line with findings from other studies which 
have reported IBI infections to show decreasing case fatality rates with increase age (with infants <3 
months of age experiencing the highest case fatality rates in children under 5 years of age) (2). A 
study in Switzerland showed that sepsis episodes in healthy children beyond the neonatal period 
were significantly less likely to result in death compared to episodes in neonates as well as children 
with comorbidities (p-value<0.001) (16). Receipt of PCV9, sex and prematurity did not have an effect 
on the severity of the outcome.   
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4.6 Description of Klebsiella spp IBI in the cohort 
This analysis found that risk factors for invasive infections due to Klebsiella spp included HIV 
infection and PCV9 vaccination. The Klebsiella spp events in this cohort were unlikely to constitute 
an outbreak since the events were spread out over the follow up period and were found to be 
community-acquired (since infected children had no previous record of being hospitalised). Although 
other studies have indicated that Klebsiella spp are significant bloodstream pathogens in South 
African children (51), the link between increased incidence in PCV-vaccinated children has not been 
documented. This requires further monitoring.   
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4.7 Limitations 
Person-time calculations were done with censoring occurring at each participant’s fifth birthday or 
date of death (for participants that were reported to have died during hospital admission). Since 
active surveillance was not done on all enrolled participants, it was assumed that participants 
survived until their fifth birthday unless a death was reported. Censoring would have incorrectly 
occurred at age 5 for participants that died after being discharged, refused health treatment or died 
without being admitted to CHBAH. The limitation of this passive surveillance system is that incidence 
may be underestimated due to the inflation of the denominator. There may also be an 
underestimation of incidence in the youngest age category as participants were eligible for 
enrolment up to 12 weeks of age (despite recommendation of first vaccination at 6 weeks), so the 
surveillance may have missed events for children that were enrolled late.  
Not all participants in the Soweto PCV9 efficacy trial had known HIV status as HIV testing was not 
done routinely at the time. During the study, HIV testing was only done on study participants 
admitted to CHBAH in whom HIV was clinically suspected, hence participants that were not 
hospitalised were assumed to be HIV-uninfected (34). Since only 13.3% of the cohort had confirmed 
HIV status recorded, this assumption may have led to an under-estimation of the prevalence of HIV 
infection in the PCV9 trial cohort. The under-estimation may have been associated with an inflation 
of IBI incidence rates amongst HIV-infected participants in this analysis. However, as participants 
were followed up until 5 years of age, we would expect that any participant that was HIV-infected 
would have presented to the hospital at some point during this five-year period and been tested. 
Children that are slow progressors however, might not have had clinical signs of HIV disease in the 
first 5 years of life and as such would have been incorrectly classified as HIV-uninfected. In addition, 
using our assumption, the HIV prevalence in the cohort was 3.2%, which was very similar to HIV 
prevalence estimates obtained using the projections of the Actuarial Society of South Africa’s 2008 
AIDS and Demographic model for this time period (3.0%) (55). Another limitation was that HIV status 
of the mothers was unknown and hence HIV-exposure status could not be analysed for the cohort. 
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In the post-ART and PMTCT era, with significantly fewer HIV-infected children, there are a 
substantial number of HIV-exposed, -uninfected children who are themselves at risk for infectious 
disease-related morbidity and mortality (56). This raised susceptibility among HIV-exposed, -
uninfected children is only expected to last for 6-12 months after birth. Hence analysis of HIV-
exposure in the current cohort would have been beneficial for extrapolation of results and trends to 
the current setting.  
The date on which blood cultures were taken was not recorded, although it was assumed that these 
cultures were done on the date of admission (for suspected sepsis cases). Since only admission 
cultures were analysed, infections were assumed to be community-acquired. However, potential 
nosocomial infections may have been included in the analysis in instances in which a child was 
readmitted with a different pathogen within 30 days of a previous hospitalisation episode. Potential 
nosocomial infections were hence not actively excluded. As participants were enrolled at 
approximately 6 weeks of age, pathogens responsible for infections in the neonatal period were not 
assessed. Since very few participants had recorded birthweight, gestational age as a measure of 
prematurity was used in the logistic regression models as a risk factor for IBI. Birthweight would 
have been a more accurate measurement as it is more objectively measured. The measure of 
gestational age is subject to different interpretation as well as differing methods used for 
ascertainment. Furthermore, as most mothers in Soweto book at antenatal clinics at or beyond 20 
weeks of gestation, gestational age estimates are unlikely to have been accurate (57, 58).  
The indirect effect or herd immunity is an important factor contributing to the success of PCV 
vaccination programs. Specifically, PCV has been shown to reduce pneumococcal nasopharyngeal 
carriage and invasive disease in the population in both vaccinated and unvaccinated individuals (50). 
Since this study was a RCT in which only a proportion of the population was vaccinated 
(approximately 31% of the birth cohort during the time period), the indirect protection of 
vaccination through reduction of nasopharyngeal carriage could not be fully appreciated. The 
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incidence rates reported for vaccinated participants are hence likely to be an overestimation of the 
incidence rates of a population with high vaccine coverage.  
Since this is a historical cohort, it is likely that the IBI incidence has decreased since data collection. 
The introduction of PCV in 2009, and ART and PMTCT in 2004 are all likely to have contributed 
substantially to the reduction of IBI in the study setting since the study time period and hence the 
incidence rates presented here are likely to be overestimates of those expected today. The main 
purpose of this analysis, however, was to show how incidence rates may have changed for IBI 
pathogens due to PCV vaccination and that PCV vaccine in the community decreases the overall 
incidence of IBI.  
There have been reports in the literature of PCV vaccination resulting in a reduction in antibiotic-
resistant IPD (as important antibiotic-resistant serotypes are contained in the PCV vaccine) (34). This 
analysis did not interrogate antibiotic resistance in the cohort and it is thus recommended that the 
antibiotic susceptibility patterns of positive blood cultures (for S. pneumoniae and other bacterial 
pathogens) in this cohort be analysed for further information.  
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5. Chapter Five: Conclusions and recommendations  
This analysis shows that the most common IBI pathogens in a cohort of children under-5 years of age 
in Soweto from 1998 to 2005 were S. pneumoniae, E. coli and S. aureus. The incidence for all IBI 
pathogens decreased as the cohort aged, with S. pneumoniae remaining the leading pathogen in all 
age groups. HIV-infected participants had higher odds of IBI hospitalisation for all invasive 
pathogens, while PCV9 vaccination significantly reduced the odds of IBI hospitalisation which was 
directly due to the decrease in S. pneumoniae incidence in vaccinated children.  
PCV9 vaccination in this cohort resulted in a significant reduction in PCV9- and PCV9-related 
serotypes in both the HIV-infected and HIV-uninfected children (although this reduction in the HIV-
uninfected group was not large enough to result in an overall S. pneumoniae reduction and a larger 
sample size would have been required to determine a significant reduction). PCV9 vaccination was 
associated with an increase in Klebsiella spp IBI. We recommend that this increase should be 
carefully monitored. Although this analysis did not demonstrate a significant change in IBI 
attributable to S. aureus, it did show a trend towards increase in incidence in the vaccinated 
participants. The reciprocal association between S. pneumoniae and S. aureus resulting in an 
increase in S. aureus due to PCV vaccination has been reported elsewhere in the literature (59). We 
hence recommend that the S. aureus incidence rates also be carefully monitored in the era of 
widespread access to PCV. Continued monitoring of IBI incidence rates in HIV-exposed children is 
important as the HIV prevalence among pregnant women is still high in the South African setting.  
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Appendix 2: Additional tables and figures  
 
Table S1: Contaminants that were excluded from the analysis a) Number of events per group b) 
Incidence per group (per 10 000 person-years) 
a)  
Bacteria Number of Events per Group  
HIV-PCV- HIV-PCV+ HIV+PCV- HIV+PCV+ Events (% of 
total events)  
Staphylococcus 
epidermidis 
257/744 
(34.5%) 
237/744 
(31.9%)  
121/744 
(16.3%) 
129/744 
(17.3%) 
744  
(77.3%) 
Corynebacterium 
spp 
36/93 
(38.7%) 
34/93 
(36.6%) 
15/93 
(16.1%) 
8/93 
(8.6%) 
93  
(9.7%)  
Bacillus spp 25/51 
(49.0%) 
14/51 
(27.5%) 
8/51 
(15.7%) 
4/51  
(7.8%) 
51  
(5.3%) 
Propionibacterium 
spp 
6/15  
(40.0%) 
5/15 
(33.3%) 
1/15  
(6.7%) 
3/15 (20.0%)  15  
(1.6%)  
Viridans 
streptococci  
10/40 
(25.0%) 
14/40 
(35.0%)  
7/40 
(17.5%) 
9/40 (22.5%)  40  
(4.2%) 
Lactobacillus spp 0/1  
(0.0%)  
0/1  
(0.0%)  
1/1 
(100.0%)  
0/1  
(0.0%)  
1  
(0.1%) 
Coagulase-negative 
staphylococcus 
(other than S. 
epidermidis) 
1/5  
(20.0%) 
1/5  
(20.0%)  
3/5  
(60.0%)  
0/5  
(0.0%)  
5  
(0.5%)  
Peptostreptococcu
s spp 
0/1  
(0.0%)  
1/1 
(100.0%)  
0/1  
(0.0%)  
0/1  
(0.0%)  
1  
(0.1%)  
Clostridium 
bifermentans 
1/1  
(100.0%)  
0/1  
(0.0%)  
0/1  
(0.0%)  
0/1  
(0.0%)  
1  
(0.1%)  
Micrococcus spp 4/7  
(57.1%)  
2/7  
(28.6%)  
1/7  
(14.3%)  
0/7  
(0.0%)  
7  
(0.7%)  
Streptococcus spp 0/2  
(0.0%)  
0/2  
(0.0%)  
1/2  
(50.0%)  
1/2  
(50.0%)  
2  
(0.2%)  
Other Gram-
positive cocci  
0/2  
(0.0%)  
1/2  
(50.0%)  
1/2  
(50.0%)  
0/2  
(0.0%)  
2  
(0.2%)  
Neisseria subflava  0/1  
(0.0%)  
0/1  
(0.0%) 
0/1  
(0.0%) 
1/1 (100.0%)  1  
(0.1%)  
Total  340/963 
(35.3%)  
309/963 
(32.1%)  
159/963 
(16.5%)  
155/963 
(16.1%)  
963  
(100%)  
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b)  
Bacteria Incidence per group (per 10 000 person years) – 95% CI   
HIV-PCV- HIV-PCV+ HIV+PCV- HIV+PCV+ Total  
Staphylococcus 
epidermidis 
27.44 (24.19-
31.01)  
25.23 (22.12-
28.66)  
500.88 
(415.62-
598.49)  
582.88 
(486.64-
692.58)  
387.08 
(359.76-
415.93) 
Corynebacterium 
spp 
3.84 (2.69-
5.32)  
3.62 (2.51-
5.06)  
62.09 (34.5-
102.41)  
36.15 (15.61-
71.23)  
48.39 (39.05-
59.28) 
Bacillus spp 2.67 (1.73-
3.94)  
1.49 (0.81-
2.50)  
33.12 (14.30-
65.25) 
18.07 (4.92-
46.28)  
26.53 (19.76-
34.89) 
Propionibacterium 
spp 
0.64 (0.24-
1.39)  
0.53 (0.17-
1.24)  
4.14 (0.10-
23.06) 
13.56 (2.80-
36.61)  
7.80 (4.37-
12.87) 
Viridans 
streptococci  
1.07 (0.51-
1.96)  
1.49 (0.81-
2.50)  
28.98 (11.65-
59.70) 
40.67 (18.60-
77.20) 
20.81 (14.87-
28.34) 
Lactobacillus spp 0.00 (0-0.39) 0.00 (0.00-
0.39)  
4.14 (0.10-
23.06) 
0.00 (0.00-
16.67)  
0.52 (0.1-2.90) 
Coagulase-negative 
staphylococcus 
(other than S. 
epidermidis) 
0.11 (0.00-
0.59) 
0.11 (0.00-
0.59) 
12.42 (2.56-
36.29)  
0.00 (0.00-
16.67)  
2.60 (0.84-
6.07) 
Peptostreptococcu
s spp 
0.00 (0-.00-
0.39) 
0.11 (0.00-
0.59)  
0.00 (0.00-
15.27)  
0.00 (0.00-
16.67)  
0.52 (0.13-
2.90) 
Clostridium 
bifermentans 
0.11 (0.00-
0.59)  
0.00 (0.00-
0.39)  
0.00 (0.00-
15.27)  
0.00 (0.00-
16.67)  
0.52 (0.01-
2.90) 
Micrococcus spp 0.43 (0.12-
1.09)  
0.21 (0.03-
0.77)  
4.14 (0.10-
23.06) 
0.00 (0.00-
16.67)  
3.64 (1.46-
7.50) 
Streptococcus spp 0.00 (0.00-
0.39)  
0.00 (0.00-
0.39)  
4.14 (0.10-
23.06) 
14.52 (0.11-
25.18)  
1.04 (0.13-
3.76) 
Other Gram-
positive cocci  
0.00 (0.00-
0.39)  
0.11 (0.00-
0.59)  
4.14 (0.10-
23.06)  
0.00 (0.00-
16.67)  
1.04 (0.13-
3.76) 
Neisseria subflava  0.00 (0.00-
0.39)  
0.00 (0.00-
0.59) 
0.00 (0.00-
15.27)  
4.52 (0.11-
25.18)  
0.52 (0.13-
2.90) 
Total  36.30 (32.55-
40.38)  
32.90 (29.33-
36.78)  
658.18 
(559.85-
768.81)  
700.36 
(594.45-
819.71)  
501.02 
(469.87-
533.69) 
 
Abbreviations: HIV-PCV- = HIV-uninfected placebo recipients; HIV-PCV+ = HIV-uninfected PCV9 recipients; HIV+PCV- = HIV-
infected placebo recipients; HIV+PCV+ = HIV-infected PCV9 recipients; PCV9 = 9-valent pneumococcal conjugate vaccine. 
 
 
 
55 
 
Table S2: Number of IBI hospitalisations during the follow up period stratified by age group, sex, PCV9 vaccination status, HIV status and prematurity 
Characteristic S. 
pneumoniae   
PCV9 
serotypes*  
Non-PCV9 
serotypes*  
Hib  E. coli   S. aureus  Klebsiella 
spp 
Salmonella 
spp 
Other**  All  
Overall 154 109 26 23 84 29 18 26 61 395 
Age Group  
<6 months***  
 
43 
 
23 
 
10 
 
6 
 
33 
 
15 
 
9 
 
8 
 
28 
 
142 
6-11 months 30 19 6 8 25 4 3 5 11 86 
12-17 months 22 18 2 3 9 3 2 6 7 52 
18-23 months 13 11 11 1 5 2 1 1 5 28 
24-35 months 17 13 3 2 10 1 3 6 6 45 
36-59 months  29 25 4 3 2 4 0 0 4 42 
Sex  
Male  
 
83 
 
62 
 
11 
 
11 
 
50 
 
18 
 
10 
 
11 
 
37 
 
220 
Female 71 47 15 12 34 11 8 15 24 175 
Vaccination 
status  
PCV9  
 
 
55 
 
 
35 
 
 
15 
 
 
11 
 
 
33 
 
 
19 
 
 
14 
 
 
12 
 
 
26 
 
 
170 
Placebo 99 74 11 12 51 10 4 14 35 225 
HIV Status  
Infected   
 
116 
 
83 
 
20 
 
14 
 
54 
 
10 
 
10 
 
17 
 
29 
 
250 
Uninfected  38 26 6 9 30 19 8 9 32 145 
Prematurity 
Term  
 
138 
 
96 
 
24 
 
18 
 
73 
 
27 
 
13 
 
24 
 
52 
 
345 
Preterm  15 12 2 5 11 2 5 2 9 49 
Season 
Summer 
 
72 
 
47 
 
13 
 
8 
 
40 
 
13 
 
6 
 
11 
 
24 
 
174 
Winter  82 62 13 15 44 16 12 15 37 221 
Study group  
HIV+PCV+ 
 
39 
 
27 
 
10 
 
6 
 
22 
 
7 
 
7 
 
6 
 
13 
 
100 
HIV+PCV- 77 56 10 8 32 3 3 11 16 150 
HIV-PCV+ 16 8 5 5 11 12 7 6 13 70 
HIV-PCV- 22 18 1 4 19 7 1 3 19 75 
56 
 
* PCV9 serotypes included: 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F; vaccine-related serotypes included: 6A, 19A and 19B (33). Vaccine-serotypes and non-vaccine serotypes do not add up to the 
total pneumococcal events as latex positive, culture negative S. pneumoniae cultures were not serotyped 
** Other bacterial infections include: Streptococcus spp (n=11), P. aeruginosa (n=9), N. meningitidis (n=8), A. lwoffii (n=6), Campylobacter spp (n=6), E. faecalis (n=6), C. albicans (n=3), 
Alcaligenes spp (n=2), M. morganii (n=2), M. tuberculosis (n=2), C. freundii (n=1), E. vulneris (n=1), non-typable H. influenzae (n=1), H. parainfluenzae (n=1), M. catarrhalis (n=1),  and S. flexneri 
(n=1) 
***Enrolment took place at 28-84 days old hence the <6 month group excludes children under 28 days  
Abbreviations: HIV-PCV- = HIV-uninfected placebo recipients; HIV-PCV+ = HIV-uninfected PCV9 recipients; HIV+PCV- = HIV-infected placebo recipients; HIV+PCV+ = HIV-infected PCV9 
recipients; PCV9 = 9-valent pneumococcal conjugate vaccine. 
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42.1%
52.6%
5.3%
38.5%
61.5%
6.2%
68.8%
18.8%
6.2%
23.1%
76.9%
HIV-PCV- (n=19) HIV-PCV+ (n=13)
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Gram positives Gram negatives
Fungal TB
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Pie charts showing the constitution of the group labelled as ‘Other’ for the purposes of the analysis. 
‘Other’ was split into Gram positives (Streptococcus spp, E. faecalis), Gram negatives (P. aeruginosa, Campylobacter spp, M. catarrhalis, Alcaligenes spp, M. 
morganii, A. lwoffii, S. flexneri, N. meningitidis, H. parainfluenzae, C. freundii, E. vulneris, H. influenzae), fungal (C. albicans) and M. tuberculosis.  
Abbreviations: HIV-PCV- = HIV-uninfected placebo recipients; HIV-PCV+ = HIV-uninfected PCV9 recipients; HIV+PCV- = HIV-infected placebo recipients; 
HIV+PCV+ = HIV-infected PCV9 recipients; TB = M. tuberculosis.
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Table S3: Number of invasive S. pneumoniae events stratified by serotype for HIV-infected and –
uninfected as well as PCV9 and control groups 
 * PCV9 serotypes included: 1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F as well as **PCV9-related serotypes 6A, 19A and 19B.  
Abbreviations: PCV9 = 9-valent pneumococcal conjugate vaccine. 
 
 
Serotype HIV-Infected  HIV-Uninfected   Total  
PCV Placebo Total  PCV Placebo Total   
1* 0 1 1 1 4 5 6 
3 1 0 1 0 1 1 2 
4* 0 1 1 1 2 3 4 
5* 0 1 1 0 1 1 2 
6A** 4 18 22 1 0 1 23 
6B* 3 10 13 1 2 3 16 
8 0 0 0 2 0 2 2 
9V* 3 2 5 0 3 3 8 
10A 1 0 1 0 0 0 1 
12F 0 1 1 0 0 0 1 
13 0 1 1 0 0 0 1 
14*  3 8 11 0 2 2 13 
15A 1 4 5 0 0 0 5 
15B 1 0 1 1 0 1 2 
15C 1 1 2 0 0 0 2 
15F 1 0 1 0 0 0 1 
16F 1 0 1 0 0 0 1 
17F 1 0 1 0 0 0 1 
18C* 1 0 1 1 1 2 3 
19A** 3 6 9 3 1 4 13 
19B** 0 1 1 0 1 1 2 
19F* 4 3 7 0 1 1 8 
23A 0 1 1 0 0 0 1 
23F* 6 5 11 0 1 1 12 
29 1 0 1 0 0 0 1 
34 0 0 0 1 0 1 1 
38 1 0 1 0 0 0 1 
99 0 1 1 0 0 0 1 
PCV9- and 
PCV-related 
serotypes 
27 56 83 8 18 26 109 
Non-
vaccine 
serotypes 
10 10 20 5 1 6 26 
TOTAL  37 66 103 13 19 32 135 
59 
 
 
Table S4: Risk factors for coagulase-negative staphylococcus IBI 
 
* Adjusted for PCV9 vaccination, sex, HIV infection status and prematurity.  
Abbreviations: OR = odds ratio; PCV9 = 9-valent pneumococcal conjugate vaccine; Ref = referent. 
 
Table S5: Risk factors for coagulase-negative staphylococcus IBI (for children under 3 months of age) 
 Univariate  Multivariate* 
OR  p-value  OR p-value  
Vaccination  
Control Ref - Ref - 
PCV9 1.00 (0.72-1.41)  0.980 1.05 (0.75-1.47)  0.791 
Sex 
Female Ref - Ref - 
Male 1.38 (1.00-1.95)  0.065 1.32 (0.94-1.87)  0.112 
HIV 
Uninfected Ref - Ref - 
Infected 7.57 (5.30-10.82)  <0.001 6.80 (4.72-9.79)  <0.001 
Prematurity   
Term Ref - Ref - 
Preterm 2.99 (1.94-4.59)  <0.001 2.17 (1.40-3.36)  <0.001 
 
*Adjusted for PCV9 vaccination, sex, HIV infection status and prematurity.  
Abbreviations: OR = odds ratio; PCV9 = 9-valent pneumococcal conjugate vaccine; Ref = referent 
 
 
 
 
 Univariate  Multivariate*  
OR  P-value OR  P-value 
Vaccination  
Control  Ref  - Ref - 
PCV 0.95 (0.82-1.10) )  0.481 1.00 (0.86-1.14) 0.890 
Sex 
Female  Ref  - Ref - 
Male  1.39 (1.20-1.61)   <0.001 1.34 (1.15-1.55) <0.001 
HIV 
Uninfected    Ref  - Ref - 
Infected  7.74 (6.63-9.03)   <0.001 7.07 (6.04-8.28) <0.001 
 Prematurity  
Term  Ref  - Ref  - 
Preterm 2.78 (2.30-3.36)   <0.001 2.06 (1.69-2.50) <0.001 
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Table S6: Incidence (per 10 000 person-years) of non-contaminated CSF cultures detected during 
hospitalisation during the follow up period 
Bacteria Number of events  Percentage (%) Incidence (10 000 PYs) 
– 95% CI  
S. pneumoniae  48 51.6 24.97 (18.41-33.11) 
Hib 7 7.5 3.64 (1.46-7.50) 
E. coli   7 7.5 3.64 (1.46-7.50) 
S. aureus 1 1.1 0.52 (0.01-2.90) 
Klebsiella spp 2 2.2 1.04 (0.13-3.76) 
Salmonella spp 1 1.1 0.52 (0.01-2.90) 
Other * 27 29.0 14.05 (9.26-20.44) 
Total  93 100 48.39 (39.05-59.28) 
* Other = Neisseria meningitidis (n=8); Streptococcus spp (excluding S. pneumoniae) (n=4); M. tuberculosis (n=2); P. 
aeruginosa (n=2); A. lwoffii (n=1); Campylobacter spp (n=1); S. flexneri (n=1); not specified (n=8) 
Abbreviations: Hib = H. influenzae type b; PY = person years. 
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Figure S2: The proportions of pathogens detected in CSF cultures during hospitalisation by HIV status 
and PCV9 vaccination status 
Other bacterial infections include: N. meningitidis (8.6%); Streptococcus spp (excluding S. pneumoniae) (4.3%); M. 
tuberculosis (2.2%); P. aeruginosa (2.2%); A. lwoffii (1.1%); Campylobacter spp (1.1%); S. flexneri (1.1%); not specified 
(8.6%) 
Abbreviations: Hib = H. influenzae type b; HIV-PCV- = HIV-uninfected placebo recipients; HIV-PCV+ = HIV-uninfected PCV9 
recipients; HIV+PCV- = HIV-infected placebo recipients; HIV+PCV+ = HIV-infected PCV9 recipients. 
 
 
 
 
 
